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ABSTRACT
EPITOPE MAPPING AND MECHANISMS OF ACTION OF HUMAN INFLUENZA
ANTIBODIES DERIVED FROM TRANSCHROMOSOMIC CATTLE
RONGYUAN GAO
2020
Influenza remains a global health risk and challenge. Currently, NA inhibitors are
extensively used to treat influenza, but their efficacy is compromised by the emergence of
drug resistant variants. Antibodies targeting influenza A virus surface glycoproteins are
critical components of influenza therapeutic agents and may provide alternative strategies
to the existing countermeasures. This study characterized both polyclonal and monoclonal
antibodies produced from the transchromosomic (Tc) cattle platform. A polyclonal
antibody, designated SAB-100, was generated from Tc cattle after immunized with
H1N1,H3N2, and influenza B virus. The peptide-based Enzyme-linked immunosorbent
assay shows that the polyclonal antibody recognizes three distinct epitopes, one out of three
is located in HA2 and is highly conserved among different subtypes of HAs. This work
shows the antigenic moieties of influenza HA, which may assist the design and
development of vaccines and therapeutic agents.
Next, one human monoclonal antibody (mAb), 53C10, also generated from the Tc
cattle platform was characterized. This mAb was capable of neutralizing diverse clades of
the H1 subtype. In vitro selection of antibody escape mutants reveals that 53C10 recognizes
a novel non-continuous epitope that overlaps with the receptor binding site (RBS) and the
introduction of three substitutions in hemagglutinin (HA) can completely abrogate
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antibody recognition. Further characterization showed that two substitutions in the escape
mutant may not affect antibody binding but may serve as compensatory substitutions.
Numerous studies confirmed the protective role of neutralizing antibodies. Contrarily,
non-neutralizing antibodies and their therapeutic potential are less well defined. Our
enzyme-linked immunosorbent assay (ELISA), western blot and flow cytometry assays
demonstrated that one human mAb isolated from Tc cattle recognizes diverse influenza A
HAs from subtype H1. Despite the broad binding to H1 HAs, 38C2 mAb demonstrated no
detectable neutralizing activities against H1N1 virus in vitro. Further investigation of
38C2’s mechanism of action revealed that this monoclonal antibody can induce potent
antibody-dependent cellular cytotoxicity (ADCC) in vitro. There is a correlation between
the binding affinity of 38C2 to HA and the potency of ADCC induced by 38C2. Detailed
epitope mapping and structural modeling demonstrate that 38C2 binding to a linear epitope
which located in the HA trimer interface. Conservative analysis show that the epitope
recognized by 38C2 is highly conserved in H1 HA.
In summary, the results of our neutralizing antibody may indicate the potential role
of 53C10 in the treatment of H1 influenza virus infection in humans. Our non-neutralizing
antibody characterization emphasizes the crucial role of Fc-effector functions and may
provide a plausible way to develop a universal influenza vaccine.
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Chapter 1. Introduction and objectives
Influenza viruses cause severe respiratory illness, leading to 290,000-650,000 deaths
annually worldwide as estimated by world health organization (WHO) [1]. Influenza
viruses consist of four known genera, A, B, C, and D, which belong to the family
Orthomyxoviridae [2]. Of these four genera, influenza A virus causes the greatest mortality
and is the most common cause of both seasonal and pandemic influenza outbreaks.
Influenza B virus can cause seasonal influenza, while the influenza C virus can infect
children with mild respiratory symptoms. Little is known about the impact of recently
discovered influenza D on human health [3,4].
Hemagglutinin (HA) and neuraminidase (NA) are the two primary viral surface
glycoproteins involved in critical steps of the influenza life cycle. The trimeric HA protein
consists of two domains: the head domain and the stalk domain. HA head domain contains
the receptor binding site (RBS) that binds to sialic acids (SAs) on the susceptible cells to
initiate the virus replication cycle. After the virus is endocytosed, the fusion peptide in the
HA stalk is exposed to mediate the membrane fusion towards releasing viral
ribonucleoprotein (RNP) complex into the cytoplasm and subsequently to the nucleus of
infected cells [2]. After the newly assembled influenza virus buds from the infected cell,
HA on the virion still interacts with the SA receptors on the host cell membrane. The
tetrameric NA spike functions to release the viral progeny through cleaving α-ketosidic
linkage between the SA and an adjacent sugar residue [5].
The HA and NA proteins are also highly immunogenic and antibodies targeting both
glycoproteins can be isolated after natural infection or vaccination. Through binding to
viral surface proteins HA and NA, antibodies can block the essential steps in the virus
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replication cycle, thereby limiting the spread of infection. Due to the host immune pressure
and error-prone RNA polymerase, HA and NA are very plastic and display differences in
antigenic properties. According to the antigenic difference, influenza A viruses are divided
into 18 HA (H1–H18) and 11 NA (N1–N11) subtypes [6]. According to the Weekly U.S.
Influenza Surveillance Report released by CDC, H1N1(pdm09) and B/Victoria lineage
viruses are equally dominant and responsible for the majority of death cases during 20192020 influenza season [7].
At present, anti-influenza virus drugs and vaccines are the major measures to combat
influenza [8]. The anti-influenza virus inhibitors are designed to target the M2 protein
(amantadine and rimantadine) and NA protein (zanamirvir and oseltamivir) to block viral
replication. The extensive usage of M2 inhibitors is hindered by the rapid emergence of
resistant mutants. The NA inhibitors exhibit a broader antiviral spectrum compared to the
M2 inhibitors, but their efficacy is also significantly compromised by the emergence of
resistant variants [9]. Therefore, there is an urgent demand for influenza therapeutics or
vaccines with the broad protective spectrum to improve public health.
Antibodies are the main players of vaccines and can also be employed for therapeutic
purposes as alternative strategies for viral inhibitors. The antibody-based treatment has
been developed against human immunodeficiency virus (HIV) infection [10] and also
shows therapeutic potential for influenza virus infections in humans. Currently,
monoclonal antibodies (mAbs) against various influenza proteins, such as HA, NA, M2,
and NP have been identified and characterized. Given the high conserved property,
antibodies against NP and M2 have been gathered numerous attention. Antibodies against
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NP and M2 are capable of conferring heterosubtypic protection against influenza infection
[11,12].
Recently, research on NA-specific mAbs has also begun to attract more attention as
they may shed light on the future design of universal vaccines. Compare to the high
plasticity of HA head domain, NA demonstrates a relatively slow antigenicity change [13].
Therefore, antibodies targeting NA may exhibit a broad binding-spectrum. Stadlbauer et
al. described that three human antibodies were cross-reactive to NAs from both influenza
A and B viruses [14]. These anti-NA antibodies can employ different mechanisms to inhibit
virus replication, not only block progeny viral release but also elicit ADCC activity in vitro.
Four major mechanisms are likely employed by antibodies targeting HA to suppress
influenza virus replication. First, some anti-HA head antibodies can disrupt virus
attachment by binding to the receptor-binding site (RBS), and they are termed as “classic
neutralizing antibodies”. Their neutralizing activity can be evaluated by the standard
neutralization and hemagglutination inhibition (HI) assays. However, the majority of these
antibodies targeting the RBS are strain-specific. Given the high mutation rate in the HA
head domain, virus may readily escape from neutralizing antibody selective pressure via
introducing mutations, making mAbs protective efficacy significantly reduced. Some
mutations in NA may also facilitate the resistance to HA-specific mAbs, underscoring the
cooperative role of HA and NA for robust virus replication [15]. Interestingly, Qiu et al.
reported one antibody showed strong neutralization and HI activity, but it recognized an
epitope not overlapping with RBS [16]. The antibody binding orientation leads to the steric
hindrance of the RBS domain as its Fc domain may block the RBS from binding to the
receptors.
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Notably, some antibodies targeting the conserved epitopes in RBS display broad
neutralizing activity. Ekiert et al. demonstrated that one mAb binding to the conserved
region of RBS can neutralize strains from group 1 and group 2 viruses [17]. Lee et al.
reported one antibody, F045-092, can neutralize H1N1, H2N2, H3N2, and H5N1 viruses
by recognizing an epitope in the RBS [18].
Second, some antibodies that recognize epitopes in the vestigial esterase (VE)
subdomain of HA head can interfere with progeny virus release. Comparing to other
domains of HA, VE subdomain is under-studied and less well defined. Extensive studies
investigating VE-targeted antibodies (VE-Abs) reveal that VE subdomain is highly
conserved in one subtype, but variable among other subtypes [19]. Therefore, VE-Abs
typically exhibit cross-clade neutralizing activity in one subtype, but no detectable crosssubtype anti-viral activity [20,21]. Multiple mechanisms are employed by VE-Abs to
neutralize virus. Chai et al. demonstrated that one human antibody targeting VE subdomain
of influenza B virus, 46B8, was capable of neutralizing virus by inducing antibodydependent cellular cytotoxicity (ADCC) activity and inhibiting HA-mediated membrane
fusion [22]. Bangaru et al. reported that one broadly binding VE-Ab, H3v-47, neutralized
H3N2 virus by preventing progeny viruses budding and eliciting ADCC activity [23]. The
broad-spectrum protective activity of VE-Abs suggests that epitopes of VE subdomain may
be utilized in the immunogens to elicit broadly neutralizing antibodies for therapeutic
purposes.
Third, antibodies targeting the HA stalk domain can block membrane fusion by
interrupting the essential conformational change in HA stalk, thereby inhibiting virus
replication [24]. Since the HA stalk domain is less prone to mutate, antibodies targeting
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this region are generally more broadly reactive [25]. Therefore, the HA stalk domain is a
promising target for universal influenza vaccine. Several broad-spectrum anti-stalk
antibodies are being evaluated in clinical trials [24].
However, the HA stalk-based vaccines usually induce less potent antibodies and weak
protection in vivo [26]. Therefore, the novel strategies, such as chimeric HA and
hyperglycosylation of HA head, are required to induce broadly protective HA stalk-specific
antibodies for optimal protection. Of note, the addition of glycans may lead to the steric
hindrance of the antigenic sites, which may facilitate the virus evasion from antibody
pressure. Furthermore, the addition of glycans may also leads to the fitness reduction,
compensatory substitutions are required [27]. It is reported that virus may escape from
broadly neutralizing anti-stalk antibodies by inducing substitutions promote viral fusion
and/or reduce antibody binding [28].
Four, some antibodies targeting HA can induce Fc-effector functions [29-31]. Fceffector function also serves as a crucial mechanism in combating influenza virus infection.
Details about Fc-effector functions induced by mAbs are described in literature review in
this dissertation.
Apart from the B cell responses, T cell immunity also plays a crucial role in antiinfluenza activities. Cytotoxic T lymphocytes (CTL) are capable of eliminating viralinfected cells by recognizing the viral epitopes expressed by the major histocompatibility
complex (MHC). The highly conserved epitopes from internal proteins, such as NP, PB1,
and M1, can be recognized by CTL, inducing durable and broad cross-protection [32]. It is
reported that NP is the primary target in T cell responses [33]. However, the CTL-mediated
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protection has a weak potency and its detailed mechanism is not well characterized in
details [34].
This dissertation focuses on the characterization of polyclonal and monoclonal
antibodies generated from Tc cattle. Currently, neutralizing antibodies are wellcharacterized and they can confer protection in vivo, whereas the non-neutralizing
antibodies (nnAbs) and their therapeutic potential are less well defined. Our first hypothesis
is that the nnAb provides protection through mechanisms different from classical
neutralizing antibodies. The second hypothesis is that the antibodies targeting the head
domain may also elicit antibody-dependent cellular cytotoxicity (ADCC) activity. The
third hypothesis is that the virus may evade from neutralizing antibody pressure at the cost
of viral fitness, which may be compensated by glycosylation and/or compensatory
substitutions.

Objectives
The first objective of this dissertation was to identify linear B cell epitopes recognized
by polyclonal and monoclonal antibodies generated from Tc cattle. The second objective
was to elucidate the protective mechanisms employed by nnAbs. The third objective was
to investigate the mechanism of viral evasion from neutralizing antibody pressure.
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Chapter 2. Literature review
2.1 Structure of influenza A virus
The spherical influenza virion has two major glycoproteins expressed at its surface,
hemagglutinin (HA) and neuraminidase (NA) (Fig. 2.1). According to the antigenic
difference, influenza A virus can divide into 18 HA (H1–H18) and 11 NA (N1–N11)
subtypes [1]. Matrix protein 2 (M2) is also expressed at the viral surface, although its
expression is relatively lower than HA and NA. All these surface expressed proteins
assist virus assembly [2]. Matrix protein 1 (M1) is expressed beneath viral membrane and
it is crucial for maintaining viral integrity [3]. A segmented RNA genome was in the
interior of influenza virion. Each viral RNA bound to the polymerase complex and
nucleoprotein (NP) to form a viral ribonucleoprotein (vRNP) [4]. The polymerase
complex contains three proteins: polymerase basic proteins 1 (PB1), 2 (PB2) and acidic
protein A (PA), which is the target of antiviral compounds [5].
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Figure 2.1 Schematic view of influenza virion. Hemagglutinin (HA),
neuraminidase (NA) and matrix protein 2 (M2) are the proteins expressed on virus
membrane. Trimeric HA protein consists of HA head and HA stalk. Viral
ribonucleoprotein (vRNP) is composed of vRNA and nucleoprotein (NP, light
purple). Viral polymerase complex includes polymerase basic proteins 1 (PB1,
blue), 2 (PB2, tan) and acidic protein A (PA, light yellow). The matrix protein
(M1) is a multi-functional protein involved in influenza virion assembly and
infection.
2.2 Non-neutralizing antibodies and ADCC activity
Previous antibody protective efficiency was measured by their capability to prevent
HA binding via neutralization assay and hemagglutination inhibition assay [6,7],
antibodies without these functions were less well defined. However, increasing evidence
suggests that non-neutralizing antibodies (nnAbs) can confer protection via multiple
mechanisms without disturbing virus entry or membrane fusion, such as activating
complement, increasing phagocytosis, targeting internal viral proteins and eliciting
fragment crystallizable (Fc)-effector functions [8-11]. Unlike neutralizing antibodies,
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nnAbs do not bind to the RBS in the HA head and fail to inhibit hemagglutination.
Therefore, these antibodies demonstrate no detectable in vitro hemagglutination inhibition
(HI) titer or neutralizing activity commonly considered as the benchmark standard of
vaccine efficacy. Nonetheless, recent studies have validated that nnAbs can also contribute
to the vaccine-elicited protection against influenza virus infection in vivo [12,13]. The
protective mechanisms employed by nnAbs depend on the engagement with effector cells
and consist of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent
cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP). ADCP
also assists in the elimination of virus-infected cells and protects against influenza virus
infection in a mouse model [14]. Importantly, these nnAbs can be induced by vaccination
in humans [10,12,15]. Jegaskanda et al. showed that ADCC-mediated antibodies (ADCCAbs) can be induced from monovalent inactivated influenza A(H1N1) virus vaccine, high
titers of ADCC-Abs can contribute to lower virus replication and reduced clinical
symptoms [12]. Zhong and colleagues demonstrated that both ADCC-Abs and neutralizing
antibodies can be elicited by influenza vaccination [15].
The mechanism of the antibody-triggered Fc-effector functions is well understood.
The antibody Fc region interacts with the FcγRIIIa (CD16a) on the surface of the Fc
receptor-bearing cells, primarily natural killer cells (NK cells). After the antibodies bind
to their target viral proteins, the combined interactions activate these effector cells. The Cterminal immunoreceptor tyrosine-based activation motif (ITAM) in effector cells is
subsequently activated to stimulate the release of granzyme B and perforin by activating
signal-transduction molecules and various pathways, such as calcium-dependent pathways
and mitogen-activated protein kinase pathway (originally known as extracellular signal-
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regulated kinases pathway) [16,17]. Details of the signaling pathways initiated by Fc-Fc
receptors (FcRs) have been extensively reviewed by Nimmerjahn et al [18]. Perforins can
produce pores in the virus-infected cell surface, allowing the entry of granzyme B that
cleaves death substrate to initiate apoptosis [19]. Together, these facilitate the elimination
of influenza virus-infected cells [20]. . This Fc-receptor binding activity was also
confirmed to confer protection in animal models in the absence of neutralizing antibodies
[21].
Multiple parameters impact the potency of Fc-effector functions. FcRs expression
pattern in these cells affects the potency of Fc-effector functions. FcRs are divided into
activating and inhibitory receptors based on whether the receptor-mediated signal activates
the ITAM or the opposing immunoreceptor tyrosine-based inhibitory motif (ITIM). The
magnitude of NK cell responses critically relies on the integration of signals transduced by
ITAM and ITIM [22]. Depending on the antibody isotype, these binding receptors can
differ. FcγR, FcεR, and FcαR can recognize Fc region of IgG, IgE, and IgA, respectively
[23]. FcγRs are the most well-studied FcRs. Different FcγRs can vary significantly from
antibody binding affinity to ADCC induction [24]. In human FcRs, FcγRI(CD64),
FcγRIIa(CD32a), FcγRIIc(CD32c), and FcγRIIIa(CD16a) are activating receptors, while
FcγRIIb (CD32b) is the inhibitory receptor [25]. It is worth noting that no inhibitory
receptor is present on NK cells surface, only the activating receptor FcγRIIIa is expressed
[18]. Without the intervention of FcγRIIb as an inhibitory receptor to negatively regulate
cell activation, NK cells serve as the predominant cells that can mediate potent ADCC
responses in vivo [20].
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Although mouse FcγRs and their counterparts in humans are named similarly, they
may differ substantially in their expression pattern, antibody subclass binding affinities and
in vivo dominant FcγRs [21,25]. Some FcγRs, such as FcγRIIa, FcγRIIc, and FcγRIIIb, are
expressed in human immune cells but not in mice cells [26] and FcγRIV is expressed in
mice immune cells but not in human cells [27]. Therefore, a transgenic mouse model
consistently expressing human FcRs is needed when investigating human antibodymediated Fc-effector functions and the human FcγR contribution to antiviral response.
Smith et al. generated a mouse model without any murine FcγRs and human FcγRs genes
were inserted into the mouse genome to express functional human FcγRs [28]. These
human FcγRs were validated to mediate the cytotoxic effects of human IgG antibodies,
providing a valuable platform for therapeutic IgG antibodies studies [21].
Most therapeutic antibodies in development are IgG [29]. IgG subclasses (IgG1, IgG2,
IgG3, and IgG4 in humans) exhibited different binding affinities to FcγRs as they differ in
primary sequence and the associated structure. Of the four IgG subclasses, IgG1, IgG2, and
IgG4 are used clinically for therapeutic purposes [30], while the extensive application of
IgG3 may be hindered by the its short serum half-life [31,32]. Both IgG1 and IgG3
canmediate potent ADCC activity, while IgG2 and IgG4 have a poor ADCC function [33].
Lastly, antibody glycosylation is essential for maintaining antibody structural
conformation which is directly related to the potency of Fc-effector functions [29,34].
Many factors can affect glycosylation patterns, which include age, pregnancy and virus
infection [35-37]. However, the detailed mechanism of how antibody glycosylation impact
Fc-effector functions remains unclear. It has been demonstrated that the reduced content
of fucose can enhance ADCC activity [38]. Various approaches, such as alpha-(1,6)-
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fucosyltransferase gene knockout, have been developed to manipulate antibody
fucosylation to optimize ADCC activity [39]. Glyco-engineering and protein engineering
have emerged as the two main strategies to harness ADCC activity [40].
Antibodies mediating Fc-effector activities were isolated and characterized in
numerous studies, which suggest that these antibodies can play a critical role in tumor
clearance [17] and immunity to multiple pathogens such as human immunodeficiency virus
(HIV) [41,42], Ebola [43], dengue virus (DENV) [44] ,West Nile virus (WNV) [45] and
influenza virus [8,9]. HIV infection remains a health issue on a global scale and vaccine
candidates were developed to address this deteriorating issue. Currently, only one HIV
vaccine, RV144, shows modest efficacy (31% efficacy) and this efficacy is not associated
with neutralizing antibodies but with potent ADCC-Abs [46-50].
2.3 Antibodies induce ADCC activities through diverse innate effector cells
As Fc-FcγR interactions are required to induce ADCC, effector cells must express
FcγRs on membrane surface to facilitate Fc binding. The NK cell is not the only cell type
that has the FcγRIIIa on the membrane, other Fc receptor-bearing cells, like neutrophils,
monocytes/macrophages, granulocytes, and dendritic cells (DCs) may also play a crucial
role in mediating ADCC or ADCP for viral infected cell clearance [18,51,52]. Broadly
neutralizing mAbs targeting HA-stalk can induce ADCP by neutrophils, which indicate the
important role of neutrophils in viral clearance [53,54]. Ackerman et al. described a highthroughput flow cytometry-based assay to measure the phagocytic activity by using a
monocytic cell line [55]. In addition, Horner et al. reported the critical role of
polymorphonuclear granulocyte in mediating ADCC activity in combating malignant
diseases [56].
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2.4 In vitro assays to assess antibody-induced ADCC activities
Since the discovery of the ADCC phenomenon in 1965 by Erna Moeller [57], multiple
assays have been developed to measure ADCC activity for different purposes and are
extensively employed in vaccine study and drug discovery. To measure ADCC activities
in vitro, virus-infected target cells, antibodies, and effector cells are needed. The various
assays differ in the type of effector cells used or the way to measure the cytotoxicity, which
have contributed to high variability among the assays. Considering the complex
mechanism of ADCC, it remains questionable which assays are the most physiologically
relevant to predict the in vivo efficacy [48,58].
2.4.1 51Cr release assay
ADCC activity is measured indirectly by the release of

51

Chromium(51Cr) following

lysis of virus-infected target cells in early studies [59-61]. In this assay, the target cells are
labeled with 51Cr and subsequently incubated with the appropriate antibody. The quantity
of 51Cr released from the lysed cells is detected by a gamma counter as a correlate of ADCC
activity [61]. However, the biohazard problem of radioisotopes plus the test’s low
sensitivity restricts the wide application of this assay. For these reasons, nonradioactive
assays with better sensitivity are later developed to assess ADCC activities [62].
2.4.2 Target cell killing assay
Flow cytometry-based ADCC assays are developed to measure ADCC activity by
using different fluorescent dyes to differentiate living and dead cells [62,63]. In this assay,
PKH-67 is used to label both live and dead target cells while dead target cells and effector
cells are labeled with 7-amino actinomycin D (7-AAD). Instead of measuring reporter
molecules released from target cells, this assay directly measures the lysed target cells. The
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quantification of lysed target cells is determined by measuring the double fluorescent dyes
positive cells by flow cytometry. Target cell death in the absence of antibody is used as a
background control. In 1990, Radosevic et al. reported their ADCC assay using different
fluorochromes for cell staining with similar principles [64]. Compared to other ADCC
measurement assays, this flow cytometry-based assay has a number of advantages such as
simplicity, sensitivity, accessibility, which gains popularity in many laboratories [64].
2.4.3 NK cell activation assay
NK cell activation assay is employed extensively to evaluate ADCC activities in vitro
due to its high-throughput and precision [8,21,49,65,66]. In this flow cytometry-based
assay, recombinant proteins or virus-infected cells are coated in plates followed by the
addition of antibody and peripheral blood mononuclear cells (or NK cell lines). Lysosomalassociated membrane protein-1 (LAMP-1 or CD107a) is a cell marker expressed on the
NK surface and is employed in this assay to identify NK cells’ functional activities as the
expression level of CD107a is highly correlated with cytokine secretion from activated NK
cells [67,68]. Therefore, the potency of ADCC activities can be determined indirectly by
measuring the activation marker CD107a expression on the NK cell surface. This assay has
been widely used to assess ADCC activities evoked by antibodies against the influenza
virus and HIV [69,70].
2.4.4 ADCC reporter bioassay
This bioluminescent reporter assay is designed to determine ADCC activities by the
measurement of firefly luciferase expression in effector cells [71]. A modified Jurkat stable
cell line expressing FcγRIIIa is used as effector cells and expresses firefly luciferase when
activated by nuclear factor of activated T cells (NFAT)-response element during the time
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when FcγRs are bound by Fc portion of the antibody. This cell line is developed in a simple
thaw-and-use format which reduces the high inter-assay variability and greatly increases
the throughput. This commercially available assay has been employed to quantify ADCC
activities against influenza infections [9,72-76]. However, this assay measures the signal
transduced in activated effector cell as a readout, not lysed target cell.
2.5 ADCC induced by anti-HA antibodies
2.5.1 HA stalk-targeting mAbs can mediate robust ADCC activities
The HA stalk region, in contrast to the HA head region, is less immunogenic. The
antigenic subdominance of HA stalk region may be due to the steric shielding of HA head
domain, making it less accessible to the humoral immunity [77]. Therefore, antibodies
against the stalk region are not readily stimulated and detected in natural infection of
humans. Nevertheless, low levels of stalk-specific B cells are detected in influenza patients
[78]. Furthermore, anti-stalk antibodies with broad neutralizing activity have been isolated
and characterized [79-84]. Since the stalk domain is more conserved than the head domain,
these antibodies exhibit broad-spectrum binding and are capable of conferring
heterosubtypic protection by interfering with the membrane fusion. HA stalk antibodies
were shown to neutralize subtypes in the same group or cross both group 1 and group 2
[85,86]. Ekiert et al. reported that HA stalk-binding human antibody, CR6261, neutralizes
multiple influenza subtypes from group 1 [87]. Corti et al. found that one antibody
generated from single human plasma targeting fusion sub-domain of the HA stalk could
bind and neutralize influenza A viruses from both group 1 and group 2 [86]. Dreyfus et al.
reported an HA stalk-binding antibody, CR9114, broad binding to influenza A and B HAs
and the antibody was able to confer protection against not only influenza A virus infection,
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but also influenza B virus infection in mice [81]. It should be noted that some antibodies
targeting the stalk region are not highly potent when compared to those against the head
region. This deficiency should be addressed in future studies.
Through inhibiting conformational changes essential to the membrane fusion, HA
stalk-binding antibodies can disarm influenza virus infectivity [88]. Headless HA and
chimeric HA are the two strategies to elicit HA stalk-reactive antibodies [78]. These stalkreactive antibodies exhibit higher protective potency in vivo than in vitro since these
antibodies may be capable of engaging FcγR-bearing cells to confer Fc-dependent
protection [89]. Vries et al. showed that anti-H1 stalk ADCC-antibody can be detected after
the immunization with a chimeric HA consisting of an H1 stalk domain and an irrelevant
head domain [13]. The incorporation of two anti-viral mechanisms has attracted substantial
attention in influenza vaccine design. Those HA stalk vaccine candidates were tested in
human clinical trials [90,91]. Unfortunately, clinical outcomes of HA stalk-based vaccines
are not encouraging so further clinical study was recently discontinued, which emphasizes
a critical need to discover novel vaccines that are capable of inducing potent cross-subtype
protective antibodies with ADCC activity (https://www.fiercebiotech.com/biotech/gskdumps-universal-flu-vaccine-after-interim-data-readout).
2.5.2 HI-negative head-targeting mAbs can mediate robust ADCC activities
The anti-stalk antibodies can induce ADCC activities through engaging FcγRs on NK
cells, but the role of anti-HA head mAbs in inducing ADCC remains unclear. Dilillo et al.
used an FcγR knock-out mice model to show that only anti-HA stalk mAbs can bind to
FcγRs and induce ADCC potently whereas anti-HA head mAbs inefficiently induce ADCC
activity due to poor engagement of FcγRs on the NK cell surface [21]. Other research
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groups also reported on these findings independently [65,75]. Interestingly, the
examination of anti-HA head mAbs for mediating ADCC in different studies achieved
distinct results. Recent studies suggested that some HA-head reactive antibodies (HInegative) could also engage FcγRIIIa on NK cells and mediate ADCC activity (Figure 2.2).

Figure 2.2 ADCC epitopes in HA. Antibodies targeting HA stalk, as well as HA
head including esterase domain and trimer interface, can induce potent ADCC in
vitro and elicit broad-spectrum protection in vivo. The HA structure is generated
using PyMOL. A/ California 04/2009 HA (PDB code: 3UBE) is used as a
representative HA structure to show the location of ADCC-epitopes. Influenza
HA is a trimer with each monomer comprised of HA1(wheat), vestigial esterase
domain (orange) and receptor binding domain (pink), and HA2 (palegreen). The
remaining two monomers are shown in light blue. Sialic acid is colored cyan. Side
view of the HA trimer surface is shown in (A), while the top view of the HA trimer
interface is shown in the cartoon (B) and surface (C) modes. Besides, there are
ADCC-Abs targeting HA head with unknown epitopes[92].
Firstly, epitopes in the vestigial esterase domain on HA head has also shown some
promise as an ADCC-Ab binding target (Figure 2.2A). Vestigial esterase domain-binding
antibodies were reported to function mainly by blocking viral egress similar to NA
inhibitors [81,93]. Recent studies indicated that vestigial esterase domain-binding
antibodies also elicit ADCC that may help to protect against viral infection [94]. Bangaru
and colleagues found a monoclonal antibody, H3v-47, that not only can neutralize diverse
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H3N2 viruses and block progeny viruses release but also induce potent ADCC activity,
suggesting that Fc-effector functions are critical for both HA head and stalk targeting
antibodies [94]. Interestingly, these researchers found that this multifunctional antibody
can recognize a novel epitope that spans the vestigial esterase and receptor-binding
subdomains. Similar Fc-mediated ADCC activity was observed in mAb 46B8 that targets
the vestigial esterase domain of HA head of the influenza B virus [66]. In addition, the
vestigial esterase domain is highly conserved, indicating a potential role in universal
vaccine design.
Secondly, antibodies targeting epitopes in the trimer interface may also initiate Fceffector activities. Watanabe et al. reported that antibody (S5V2-29) binding to a conserved
epitope at the HA head trimer interface can also confer potent protection in vivo by
activating FcγR-dependent effector activities [95]. Bangaru et al. discovered a broadly
protective antibody, FluA-20, which recognized a well-conserved epitope occluded in the
trimer interface and also exhibited robust Fc-mediated ADCC in vitro [96]. However, the
ADCC may not be essential to the protective role in mice. Historically, it is believed that
the trimeric HA protein is so stable that the trimer interface may not be exposed to the host
immune system and is likely unreachable by antibody but, contrarily, the epitopes
identified by these researchers suggest that the trimer interface may be accessible, at least
partially. As such, the trimer interface can be further explored as a potential target for
vaccine and therapeutics.
Thirdly, some HA-head reactive antibodies with undefined epitopes were reported to
confer protection in vivo via Fc-effector functions. DiLillio et al. demonstrated that the
broadly neutralizing HA head-reactive antibodies, 4G05 and 1F05, can induce protection
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in vivo through Fc-FcγR interactions whereas strain-specific HA head reactive antibodies
confer protection in an Fc-FcγR interactions-independent manner in vivo [92]. Also, antiH4 monoclonal antibodies binding to the HA head showed high cross-reactivity to avian
and mammalian H4 HAs and protected mice from lethal H4N6 challenges through ADCC
activity [73]. Two highly conserved epitopes, designated E1 and E2, located in HA head
of a pandemic H1N1 virus, were reported to be recognized by ADCC-Ab [62]. The
discovery of HA head reactive antibodies and conserved epitopes may assist the future
design of universal vaccines and therapeutics.
2.5.3 HI-positive head-targeting mAbs cannot mediate robust ADCC activities
As stated above, HA stalk-targeted monoclonal antibodies and HA head-targeted
antibodies with no detectable HI titer may evoke potent ADCC activities both in vitro and
in vivo. However, HI-positive antibodies that block RBS are commonly demonstrated not
to induce robust ADCC activities [74,75,97]. This failure in inducing potent ADCC activity
by HI-positive antibodies might be explained by a model proposed by Leon and colleagues
[97]. In this model, two synapses between the effector cell and the virus-infected cells are
essential for a robust ADCC response (Figure 2.3A and 2.3B). The binding between Fc and
FcγRIIIa serves as the first synapse and the interaction between viral HA head and the SA
on the effector cell forms the second synapse. These two synapses cooperatively reinforce
the connection between the target cell and the effector cell, which mediate robust ADCC
activity. The Fc-FcγRIIIa interaction alone is insufficient to induce potent ADCC activity
and the interaction of HA to SA on the effector cell is required to induce potent ADCC
function [74,75,97]. However, it remains obscure whether the SA-binding of HA activates
a signaling pathway to induce ADCC or stabilizes the interaction between antibody and
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innate immune leukocytes [97]. HI-positive antibodies may compete with the SA on the
effector cell in binding to the HA head domain, which as a result may impair the second
synapse and hence lead to the reduced ADCC activity eventually (Figure 2.3C). It was
reported that the in vitro ADCC activity induced by a stalk-reactive antibody is diminished
after the addition of a HI-positive antibody [75,97]. The blocked or diminished ADCC
activity may be due to the competitive role of neutralizing (HI-positive) antibody in binding
to the HA. Vaccination can induce both neutralizing mAbs and nnAbs, future vaccine
design should consider this delicate balance to achieve the optimal vaccine efficacy.
It is worth noting that neutralization and ADCC are not mutually exclusive. Antibodies
with both anti-viral mechanisms have also been identified and characterized in recent
studies, which demonstrated that ADCC activity could occur concurrently with a
neutralization response [15,98]. Shen et al. reported that one HA head-targeted antibody,
C12G6, can not only neutralize Yamagata, Victoria and earlier lineages of influenza B
viruses, but also inhibits the membrane fusion, virus egress, and induces an ADCC
response [98]. Notably, they also demonstrated that the potency of C12G6-mediated
ADCC activity against different viruses followed an opposite trend to its HI activity, in
which higher HI titer was found to be associated with relatively lower ADCC activity, and
vice versa.

24

Figure 2.3 Two synapses between effector cell and virus-infected cell are
essential for robust ADCC activities. The interaction between Fc and FcγRIIIa
severs as the first synapse and the interaction between viral HA head and the sialic
acid on effector cell form the second synapse, which are indispensable for
inducing potent ADCC activities (A, B). The HI-positive antibody may interfere
with the interaction between viral HA head and the sialic acid on effector cell,
leading to weak ADCC activity(C). HI assay was extensively performed to
determine the effects of antibodies in blocking the receptor engagement and
replication of the viruses. However, this evaluation may be challenged by some
emerging influenza viruses that lack the ability to agglutinate red blood cells of
various animal origins [99]. In this scenario, the cell-based virus-neutralization
assay would be suitable for the characterization of RBS binding antibodies.
2.6 ADCC to other proteins in influenza virus
Three influenza proteins are expressed on the viral membrane; HA, NA, and the Matrix
2 protein (M2) and are targets for ADCC-Abs (Figure 2.4). Although still critical in the
viral life cycle, compared to HA, NA and M2 proteins have relatively lower expression on
the viral surfaceand are not heavily targeted by the immune response. For this reason, NA
and M2 are similarly less immunogenic and have a slower antigenic drift rate. This makes
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them attractive vaccine targets and recently more studies have been exploring this avenue
[100-102].

Figure 2.4 ADCC-mediating antibodies (ADCC-Abs) targeting different
influenza antigens. HA, NA and M2 are the surface-exposed proteins and they
are capable of inducing ADCC-Abs. Antibodies targeting the conserved epitopes
in these proteins confer broad protection against divergent viruses. NP expressed
on the surface of the influenza-infected cell serves as a promising target for
ADCC-Abs.
The NA functions to cleave host SA receptors in the viral life cycle allowing the
release of nascent viruses and NA-targeted mAbs have shown a protective effect in animal
models by blocking this release mechanism [103]. Antibodies targeting NA are induced at
lower level than antibodies targeting HA after vaccination, which may be due to the
relatively less expression of NA on infected cells [104]. Some NA-targeted antibodies
require Fc-FcγR interactions to induce protection [10,104]. DiLillio et al. reported that the
broadly neutralizing NA-reactive antibodies, 3C05, can induce protective immunity in vivo
in an FcγR-dependent manner [92]. Recently, Stadlbauer et al. showed that one monoclonal
antibody generated from plasmablasts isolated from a human donor naturally infected with
the H3N2 virus, designated 1G01, showed the broadest reactive spectrum to a variety of
neuraminidases ranging from influenza A group 1 and group 2, to both influenza B virus
lineages [105]. These antibodies exhibited multiple anti-viral activities including the
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blockade of virus particle release and ADCC. The combination of two anti-viral
mechanisms contributed to the broad protection from lethal challenges in vivo by these
antibodies targeting neuraminidase antigen.
The M2 conducts the proton flux into the virion in the process of virus entry and
equilibrates pH across the trans-Golgi network in the viral maturation stage [106,107].
Response against epitopes from the ectodomain of M2 (M2e) has been shown to induce
protective immunity in mice [108]. M2e raises the hope for the universal vaccine because
of its highly conserved sequence and antibodies targeting M2e with broad protective effects
in animal models [109,110]. M2e vaccine candidates with universal vaccine potential are
tested in clinical studies [101]. It is worth noting that mAbs targeting the M2e are believed
to possess Fc-receptor dependent functions, like ADCC or ADCP [101,111-113]. Song et
al. generated an M2e-targeted mAb (Z3G1) without detectable neutralizing activity.
Interestingly, the Z3G1 antibody was found to be able to induce potent ADCC and CDC
activities in vitro as well as demonstrated protective effect in vivo [114]. Bakkouri et al.
further demonstrated the essential role of Fc receptors in anti-M2e antibody-induced
protection in mice [109]. These studies indicate that M2e-based vaccines evoke crossprotective responses in an FcγR-dependent manner. Generation and characterization of
mAbs against M2e can provide critical insights for the development of novel therapeutics
against influenza virus infection.
In addition to those proteins expressed on the viralsurface, influenza nucleoprotein
(NP) possesses highly conserved regions and is also detected on influenza virus-infected
host cells surface [115,116]. This makes NP reachable by antibody and substantial efforts
have been focused on the antiviral effects of anti-NP mAbs. The host immune response
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against NP may participate in multi-mechanisms against influenza infection. Cytotoxic T
lymphocytes (CTL) can kill target cells via the recognition of NP antigen peptides
presented by MHC-I molecules [117,118]. Berthoud et al. reported a T cell-inducing
vaccine based on NP and M1, was safe and immunogenic in older adults [119]. These
internal viral proteins have not only shown beneficial by inducing host CTL response, but
also can serve as a target for protective mAbs. Jegaskanda et al. demonstrated that mAbs
targeting M1 and NP can also elicit ADCC activity and these mAbs can be induced by
influenza vaccination and natural infection in children [12,120]. However, the protective
role of anti-NP ADCC-Abs has not been investigated in animal models. Since internal viral
proteins are more conserved, these ADCC-Abs may be considered to be included in future
universal vaccine design.
2.7 ADCC-based vaccine
To tackle the threat posed by influenza viruses, developing a universal vaccine that
can induce broad immune response against both seasonal drift strains and emerging strains
with pandemic potential is of heightening priority of influenza research. Considerable
effort has been focused on the development of therapeutic agents and universal vaccines
against influenza virus infection in recent decades. Protective antibodies that bind to
conserved epitopes in the HA head, HA stalk, NA, NP, M2e have been isolated and
characterized in the vaccine research. Most influenza vaccinology studies aim to induce a
high titer of broad neutralizing antibodies (bnAbs), which are capable of conferring broad
and durable protection against influenza virus infection, but nnAbs are less investigated.
However, it is difficult to induce bnAbs through natural infection and the effectiveness of
bnAbs was compromised after the emergence of mutant viruses. Therefore, nnAb has
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become an alternative option and numerous studies have shown the different protective
mechanisms of nnAbs and bnAbs [8,12,121]. Although no neutralizing activities can be
detected in vitro, nnAbs are competent to mediate Fc-dependent protection in vivo by
eliciting Fc-dependent effector activities. The protective property exhibited by nnAb seems
to make an equally potential candidate for universal vaccines and therapeutics against
influenza infection. Therefore, Fc-dependent effector activities should be considered and
recognized when we evaluate the protective effects of influenza therapeutic agents and
vaccine candidates.
The ADCC activity serves as a protective mechanism of HA stalk-binding antibodies
and ADCC-Abs also exhibit much greater cross-reactivity than classic neutralizing
antibodies, defining a promising direction to universal influenza vaccines. Various animal
models are used to assess the protective capacity of ADCC based vaccines, including
mouse, ferret, and non-human primates. Florek et al. reported that the ADCC-Abs induced
by vaccination are capable of inhibiting influenza virus shedding in cynomolgus macaques
[122]. A study focusing on severe human infection cases in China and Australia suggested
that antibodies from severe influenza survivors were more likely to exhibit potent ADCC
activity, which highlights critical role of ADCC in combating influenza virus infections
[123].
ADCC represents a promising strategy for vaccine development, but there are still
several questions to be addressed. First, the pre-existing neutralizing antibodies may affect
the efficacy of the ADCC-based vaccine. He et al reported that the HI-positive antibody
can inhibit the potency of ADCC activity induced by HA stalk-specific antibodies by
competing in HA binding [75] Therefore, the efficacy of the ADCC-based vaccine may be
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affected by pre-existing immunity. Besides, the activation of pre-existing B cells may
induce class switching from IgG to non-ADCC isotypes [124]. Second, vaccines that elicit
antibodies targeting the M2 or the internal proteins may confer protection against severe
influenza diseases, however, may not prevent viral infection since these antibodies mainly
recognize proteins expressed on the infected cell membrane [91]. Third, whether sufficient
ADCC-Abs can be induced by vaccination is unclear. The antigen needs to be carefully
designed and inclusion of an adjuvant is also critical to protective outcome. Four, there are
reports of antibody-dependent enhancement (ADE) in ADCC-mediating antibodies
[63,125]. In these studies, ADCC epitopes were identified and these epitope-based
vaccines were generated and tested in mice. The immunized animals with ADCC epitopes
showed robust ADCC activities but had lower survival rates in comparison with the control
group. In addition, it was shown that ADCC epitope-based vaccines might have side effects
including extra tissue damage as seen in the lungs, which was caused by the high level of
cytotoxic granules (perforin) induced by ADCC activation [63].
2.8 Strategies to augment ADCC activity
Augmenting ADCC activity is a novel research direction in cancer research. Target
cell killing activities triggered by ADCC mAbs can be substantially increased by the
addition of ADCC-promoting agents, which has attracted substantial attention in cancer
research [126,127]. Means of augmentation of these responses in cancer research might
shed light on influenza research as well. Different strategies for enhancing ADCC were
developed and employed in clinical trials in recent studies.
Considering Fc- FcγRIII interaction is required to elicit ADCC activities, the potency
of ADCC can be improved by strengthening this interaction. By selecting Fc variants with
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optimized Fc-FcγRIII affinity, antibodies can elicit a more robust activating signal to the
effector cells [51]. Lazar et al. report that Fc variant S239D/I332E has the capacity to
optimize Fc-FcγR interaction and enhance effector function both in vitro and in vivo [128].
Other strategies have been attempted to promote the secretion of cytokines by
activating effector cells. Reovirus and toll-like receptor (TLR) agonists can increase NKmediated ADCC by facilitating cytokines secretion [129]. TLR agonists can significantly
enhance ADCC by increasing the percentage of activated NK cells. It has been reported
that CpG-containing oligodeoxynucleotides (CpG ODN), a TLR9 agonist, has the effect of
promoting the cytokines secretion from activated NK cell [130].
2.9 Conclusions and future directions
The protective efficacy of influenza vaccines largely depends on the stimulation of
neutralizing antibodies. For a long period of time, vaccine efficacy has been evaluated by
HI titers of neutralizing antibodies, which correlate fairly well with traditional views on
vaccine-conferred protection. Recently it is becoming increasingly apparent that nnAbs
also play a critical role in combating influenza infection even though in vitro antiviral
activity is not detected in traditional assays [8-10]. Therefore, future evaluation of vaccine
efficacy should take Fc-dependent antiviral functions into consideration to optimize
vaccine efficacy. In this review, we have summarized multiple anti-viral mechanisms of
monoclonal antibodies with ADCC function and reveal that ADCC can overlap
substantially with other mechanisms to confer heterosubtypic protection against seasonal
and pandemic influenza. The characterization of identified nnAbs constitutes a novel
pathway that mayraise hope for the design of universal vaccines. However, there are still
questions about ADCC-Abs need to be addressed.
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(1), As mAbs mediated Fc-effector activities are epitope dependent, identifying
epitopes that can elicit nnAbs will serve as a good start for the rational design of universal
vaccines and therapeutics. Some studies show that ADCC-Abs recognize linear epitopes
[62]. Arunkumar et al. demonstrated that antibodies recognizing conformational epitopes
exhibit better protection compared to the antibodies targeting linear epitopes[9]. Further
investigation should be focused on the elucidation of which epitope type can induce a more
potent ADCC response and as a result provide better protection.
(2), ADCC-Abs may also exert immune pressure on the virus, resulting in escape
mutants that evade antibody recognition similar to what is seen with traditional neutralizing
antibodies. No influenza studies have reported ADCC-antibody escape mutants currently,
but Chung et al. demonstrated the critical amino acids in the linear epitope could mutate to
escape ADCC responses in HIV-1 [131]. Lee et al. summarized two potential mechanisms
employed by HIV-1 to resist ADCC responses, i. by directly reducing envelope antigen
expression on the infected cell surface and ii. by restricting the exposure of epitopes on the
envelope to reduce antibody binding [48,132,133]. Similar or different scenarios may
present in influenza, which may need further exploration in future studies.
(3), It remains unclear about the viral replication step(s) in which ADCC occurs. It is
indicated that ADCC activity does not intervene in viral entry and fusion and there is a
high possibility that ADCC may target the virus-infected cell, which has HA, or other virus
protein expressed [134]. This should be better investigated.
(4), Designing antibodies with enhanced capacity to induce ADCC activities against
influenza infection should be pursued vigorously. As stated above, new approaches are
being developed to augment ADCC in cancer research. These studies in cancer research
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may provide valuable insights into influenza research towards developing better vaccines
or therapeutics to improve influenza patient outcomes. Therefore, it would be beneficial to
measure the ADCC potency threshold for protective immunity. However, it is worth noting
that a more potent ADCC response may not guarantee better protection. Arunkumar et at.
reported that two non-neutralizing antibodies, KL-BHA-9B9 and KL-BHA-4C10,
exhibited uncorrelated ADCC activity with in vivo protection [9]. KL-BHA-9B9 had potent
ADCC activity in vitro but poor protection in vivo, whereas KL-BHA-4C10 conferred
strong protection in vivo but had almost undetectable ADCC in vitro. A better
understanding of ADCC activation may facilitate the mechanistic elucidation of this
phenomenon as well as other variabilities emerged in current assays.
(5), Although diverse assays have been developed to measure ADCC activity in vitro,
it is still obscure to what extent these assays can correlate to the efficacy in vivo. It is
challenging to predict ADCC-Ab efficacy in humans. The transgenic mouse model
expresses human FcγRs may better evaluate the antibody therapeutic effect in humans.
However, mice are not natural hosts of influenza and influenza viruses causing human
epidemics or pandemics typically replicate inefficiently in this animal model unless
adapted viruses are used. Non-human primate models such as rhesus macaques or
cynomolgus macaques are used in ADCC-Abs research and research findings from this
model collectively indicated that ADCC-Abs are associated with reduced shedding of
influenza viruses [8,122]. Considering the different expression patterns of FcγRs in humans
and non-human primate animals, it remains uncertain whether the correlation of treatment
outcome can be expected in humans. In this regard, clinical studies regarding ADCC-Abs
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are instrumental to examine the potential role of ADCC-Abs in combating influenza virus
infection in humans [135].
(6), It would be interesting and worthwhile to study the synergy between neutralizing
antibody and non-neutralizing antibody in vivo since both classes of antibodies will be
elicited after viral infection. The high complexity of each type of antibodies and the lack
of an ideal animal model make this investigation relatively challenging. In some cases, the
Fc-effector functions induced by nnAb can increase the potency of neutralizing antibodies
[7]. In contrast, it is also revealed that Fc-effector functions may not play any role when
there is a high dose of neutralizing antibodies [21]. One possible explanation for this is that
the function elicited by neutralizing antibodies, such as viral entry blocking or fusion
disruption, is potent and sufficient for in vivo protection alone.
(7), The interplay among ADCC-Abs targeting HA, NA, M2e and NP needs to be
investigated. It is critical to identify what antibody combination patterns can induce
synergistic protection to augment vaccine efficacy. It is reported that the NA-inhibiting
antibody elicited weak ADCC response alone, but it may cooperate with antibodies
targeting the HA stem to enhance their potency of ADCC activity [75]. NA inhibitors can
enhance Fc-dependent functions induced by anti-stalk antibody, suggesting a therapeutic
synergy between NA inhibitors and anti-stalk antibody in humans [136]. Deng et al.
demonstrated that the vaccination with double-layered nanoparticles containing HA-stalk
and M2e induced potent long-lasting immunity and full protection against divergent
influenza A viruses challenge in mice, indicating that the combination of antibodies
targeting HA stalk domain and M2e can improve the potency and breadth of vaccineinduced protection [137]. The cocktail of therapeutic antibodies may overcome the
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emergence of viral escape mutants [29]. Further studies on antibody or inhibitor interplay
may guide the better design of future universal anti-influenza countermeasures with broadspectrum protection via multiple mechanisms.
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Chapter 3. Epitope mapping of a polyclonal antibody generated from
transchromosomic cattle
Abstract
Influenza remains a global threat to human health and world economy.
Hemagglutinin (HA), the primary glycoprotein at the viral surface, is highly immunogenic
and induces potent antibody responses. Antibodies confer protection through binding to
HA or other viral proteins. Here, we characterized an anti-HA polyclonal antibody
generated from transchromosomic (Tc) cattle immunized with H1N1, H3N2 and influenza
B virus. The peptide-based Enzyme-linked immunosorbent assay (ELISA) results
demonstrated that the polyclonal antibody recognized three distinct epitopes, one of which
is located in HA2 and is highly conserved among different subtypes of HAs. These
antigenic analyses provide an important foundation for further analyzing the protective
antibodies against influenza viruses, which are generated through this novel and robust
antibody production platform.

3.1 Introduction
Influenza leads to 290,000-650,000 deaths yearly worldwide [1]. It has four
antigenically distinct genera, A, B, C, and D. Of these four types, influenza A virus is a
primary cause of seasonal influenza epidemics and also has the potential to cause a
influenza pandemic. Currently, the first-line treatment of influenza is NA inhibitors.
However, the emergence of drug-resistant mutants decreases the efficiency of treatment
outcomes.
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The discovery of antibody has revolutionized the disease diagnosis and treatment.
Polyclonal antibodies (pAbs) have been utilized as a therapeutic agent to against virus
infection [2]. pAbs are mixtures of individual antibodies recognizing diverse epitopes with
different binding affinities. Monoclonal antibodies were first isolated by hybridoma
technology by Köhler and Milstein in 1970s [3]. Currently, antibodies play crucial role in
the treatment of diverse virus infections and cancer, and some antibodies are approved by
the FDA and used clinically. Antibody engineering techniques, such as phage display,
glyco-engineering and Fc engineering methods, have been developed to improve antibody
therapeutic potential. Transgenic animals such as mice and rabbits are used for human
antibody production. To produce human antibody in a large quantity and also in a timely
manner,

humanized Tc cattle has been generated to to produce antibodies against

influenza.
In the present study, one polyclonal antibody (SAB-100) generated from Tc cattle was
characterized. SAB-100 recognized three distinctive epitopes, one of which is located in
HA2 and is highly conserved among different subtypes of HAs. The characterization of the
polyclonal antibody SAB-100 and its epitiopes may assist the design and development of
vaccines and therapeutic agents that can used to treat influenza patients.

3.2 Materials and methods
3.2.1 Generation of polyclonal antibody SAB-100
The polyclonal antibody SAB-100 was generated from transchromosomic (Tc) cattle
as reported previously [4]. Tc cattle were immunized by the inactivated H1N1, H3N2 and
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influenza B virus antigens. Polyclonal antibody, SAB-100, was isolated from the Tc cattle
plasma.
3.2.2 Peptide array
The peptide array derived from A/California/04/2009 (H1N1) HA was obtained from
BEI resources, NIAID, NIH (Cat#NR-15433). The peptide array derived from
A/Perth/16/2009 (H3N2) with the catalog number NR-19266 was also obtained from BEI
resources. Each peptide array consists of overlapping peptides covering the entire sequence
of HA protein. Each synthetic peptide is 15-mer, with 11 amino acids overlapping with the
adjacent peptides. The peptides were dissolved in Dimethyl sulfoxide (DMSO).
3.2.3 Enzyme-linked immunosorbent assay (ELISA)
The ELISA was performed as described previously [5]. 0.5 μg peptide was used to
coat the enzyme immunoassay high-binding plates for 16 hours at 4℃. Plates were washed
with PBST (PBS with 0.1% Tween-20) six times and then blocked with 300 μl blocking
buffer (PBST with 0.2% gelatin) for 2h at 37℃. After the incubation, plates were washed
with PBST six times, and then incubated with SAB-100 antibody or control antibody
(1:300 dilution in PBST containing 0.01% gelatin) for 1h at 37℃ followed by further
washing with PBST. 100 μl of 1:10,000 diluted goat anti-human IgG specific antibody
conjugated to HRP were added to the plates and incubated at 37℃ for 30 min. Plates were
then washed again and antibody binding was detected by addition of 100 μl of
tetramethylbenzidine (TMB, KPL) for 15min in the dark and stopped by adding 50 μl 4M
sulfuric acid. The optical density (OD) was read by an ELISA microplate reader (BioTek)
at an absorbance of 450 nm.
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3.3 Results
3.3.1 Identification of H1 HA peptides recognized by polyclonal antibody SAB-100
To map the epitopes recognized by SAB-100, we performed peptide ELISA. The
peptide array derived from CA/04 was tested for its reactivity against SAB-100. In the
peptide ELISA, peptide pools containing five consecutive overlapping peptides were
examined first. The reactivity against SAB-100 was determined by the optical density (OD)
value in ELISA with 0.18 OD cut-off [5]. The result showed that H1N1 peptide pools
containing peptide 71-75, peptides 91-95, peptides 131-135 and peptides 136-139, were
recognized by SAB-100 (Table 3.1). Then we narrowed down to each individual peptide
in each peptide pool and found peptide 72/73, 92/93/94, 134, and 136/137/138 were tested
positive (Table 3.2). Since peptide 72 and peptide 73 were overlapped with 11 amino acids
(underlined). This 11-amino acids segment may be a minimal epitope bound by SAB-100.
The potential minimal epitopes were also detected in peptides 92-94 and 136-138.
Table 3.1 Peptide pool sequences (A/California/04/2009, H1N1) and their reactivities
with SAB-100
Peptide

OD

sequence

location

1-5

-

1

M KA IL V VL LY T FA TA N AD TL C IG YH AN N ST D 31

HA1

6-10

-

21

CIGYHA NN STD TV DT VLE KN VT VT HSV NL LE 51

HA1

11-15

-

41

VTVTHS VN LLE DK HN GKL CK LR GV APL HL GK 71

HA1

16-20

-

61

LRGVAP LH LGK CN IA GWI LG NP EC ESL ST AS 91

HA1

21-25

-

81

NPECESLS TASS WSYI VET PSSD NGT CYPG D 1 11

HA1

26-30

-

101 SSDNGTCYPGDFIDYEEL REQLSSVS SFERF1 31

HA1

31-35

-

121 QLSSVSSFERFEIFPKTS SWPNHDSN KGVTA1 51

HA1

36-40

-

141 PNHDSNKGVTAACPHAGA KSFYKNLI WLVKK1 71

HA1

41-45

-

161 FYKNLIWLVKKGNSYPKL SKSYINDK GKEVL1 91

HA1

46-50

-

181 SYINDKGKEVLVLWGIHH PSTSADQQ SLYQN2 11

HA1

51-55

-

201 TSADQQSJYQNADTYVFV GSSRYSKK FKPEI2 31

HA1

56-60

-

221 SRYSKKFKPEIAIRPKVR DQEGRMNY YWTLV2 51

HA1

50
61-65

-

241 EGRMNYYWTLVEPGDKIT FEATGNLV VPRYA2 71

HA1

66-70

-

261 ATGNLVVPRYAFAMERNA GSGIIISD TPVHD2 91

HA1

71-75

0.198

281 GIIISDTPVHDCNTTCQT PKGAINTS LPFQN3 11

HA1

76-80

-

301 GAINTSLPFQNIHPITIG KCPKYVKS TKLRL3 31

HA1

81-85

-

321 PKYVKSTKLRLATGLRNI PSIQSRGL FGAIA3 51

86-90

-

341 IQSRGLFGAIAGFIEGGW TGMVDGWY GYHHQ3 71

91-95

0.322

361 MVDGWYGYHHQNEQGSGY AADLKSTQ NAIDE3 91

Junction
sequences
Junction
sequences
HA2

95-100

-

381 DLKSTQNAIDEITNKVNS VIEKMNTQ FTAVG4 11

HA2

101-105

-

401 EKMNTQFTAVGKEFNHLE KRIENLNK KVDDG4 31

HA2

106-110

-

421 IENLNKKVDDGFLDIWTY NAELLVLL ENERT4 51

HA2

111-115

-

441 ELLVLLENERTLDYHDSN VKNLYEKV RSQLK4 71

HA2

116-120

-

461 NLYEKVRSQLKNNAKEIG NGCFEFYH KCDNT4 91

HA2

121-125

-

481 CFEFYHKCDNTCMESVKN GTYDYPKY SEEAK5 11

HA2

126-130

-

501 YDYPKYSEEAKLNREEID GVKLESTR IYQIL5 31

HA2

131-135

0.332

521

KLESTRIYQILAIYSTVASSLVLVVSLGAIS 551

HA2

136-139

0.201

541 LVLVVS LG AIS FW MCS NG SLQ CRI CI

566

HA2

Table 3.2 Individual peptides derived from A/California 04/2009 (H1N1) HA recognized
by SAB-100
Peptide

OD

sequence

location

72

0.256

285 SDTPVHDCNTTCQTP 299

HA1

73

0.234

289 VHDCNTTCQTPKGAI 303

HA1

92

0.253

365 WYGYHHQNEQGSGYA 379

HA2

93

0.244

369 HHQNEQGSGYAADLK 383

HA2

94

0.211

373 EQGSGYAADLKSTQN 387

HA2

134

0.303

533 IYSTVASSLVLVVSL 547

HA2

136

0.185

541 LVLVVSLGAISFWMC 555

HA2

137

0.656

545 VSLGAISFWMCSNGS 559

HA2

138

0.333

549 AISFWMCSNGSLQCR 563

HA2
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3.3.2 Identification of H3 HA peptides recognized by polyclonal antibody SAB-100
By using the H3N2 peptide array, peptide pools consisted of peptide 91-95, peptide 101105 and peptide 121-125 were reactive with SAB-100 in our peptide ELISA (Table 3.3).
Next, the detailed mapping of the epitope was performed using the individual peptides in
each positive peptide pool. The results showed that peptide 93, 105 and peptide 125 were
recognized by SAB-100 (Table 3.4).
Table 3.3 Peptide pool sequences (A/Perth/16/2009, H3N2) and their reactivities with
SAB-100
Peptide

OD

Sequence

Location

1-5

-

1

MKTIIALSYILCLVFAQKLPGNDNSTATLCL 31

HA1

6-10

-

21 GNDNSTATLCLGHHAVPNGTIVKTITNDQIE 51

HA1

11-15

-

41 IVKTITNDQIEVTNATELVQSSSTGEICDSP 71

HA1

16-20

-

61 SSSTGEICDSPHQILDGKNCTLIDALLGDPQ 91

HA1

21-25

-

81 TLIDALLGDPQCDGFQNKKWDLFVERSKAYS 111

HA1

26-30

-

101 DLFVERSKAYSNCYPYDVPDYASLRSLVASS 131

HA1

31-35

-

121 YASLRSLVASSGTLEFNNESFNWTGVTQNGT 151

HA1

36-40

-

141 FNWTGVTQNGTSSACIRRSKNSFFSRLNWLT 171

HA1

41-45

-

161 NSFFSRLNWLTHLNFKYPALNVTMPNNEQFD 191

HA1

46-50

-

181 NVTMPNNEQFDKLYIWGVHHPGTDKDQIFLY 211

HA1

51-55

-

201 PGTDKDQIFLYAQASGRITVSTKRSQQTVSP 231

HA1

56-60

-

221 STKRSQQTVSPNIGSRPRVRNIPSRISIYWT 251

HA1

61-65

-

241 NIPSRISIYWTIVKPGDILLINSTGNLIAPR 271

HA1

66-70

-

261 INSTGNLIAPRGYFKIRSGKSSIMRSDAPIG 291

HA1

71-75

-

281 SSIMRSDAPIGKCNSECITPNGSIPNDKPFQ 311

HA1

76-80

-

301 NGSIPNDKPFQNVNRITYGACPRYVKQNTLK 331

HA1

81-85

-

321 CPRYVKQNTLKLATGMRNVPEKQTRGIFGAI 351

Junction
sequence

86-90

-

341 EKQTRGIFGAIAGFIENGWEGMVDGWYGFRH 371

Junction
sequence

91-95

0.204

361 GMVDGWYGFRHQNSEGRGQAADLKSTQAAID 391

HA2

95-100

-

381 ADLKSTQAAIDQINGKLNRLIGKTNEKFHQI 411

HA2

52
101-105

0.337

401 IGKTNEKFHQIEKEFSEVEGRIQDLEKYVED 431

HA2

106-110

-

421 RIQDLEKYVEDTKIDLWSYNAELLVALENQH 451

HA2

111-115

-

441 AELLVALENQHTIDLTDSEMNKLFEKTKKQL 471

HA2

116-120

-

461 NKLFEKTKKQLRENAEDMGNGCFKIYHKCDN 491

HA2

121-125

0.254

481 GCFKIYHKCDNACIGSIRNGTYDHDVYRDEA 511

HA2

126-130

-

501 TYDHDVYRDEALNNRFQIKGVELKSGYKDWI 531

HA2

130-135

-

521 VELKSGYKDWILWISFAISCFLLCVALLGFI 551

HA2

136-139

-

541 FLLCVALL GFI MWA CQK GNI RCN ICI

HA2

566

Table 3.4 Individual peptides derived from A/Perth/16/2009 (H3N2) HA recognized by
SAB-100
Peptide

OD

Sequence

Location

93

0.198

369 FRHQNSEGRGQAADL 383

HA2

105

0.215

417 EVEGRIQDLEKYVED 431

HA2

125

0.194

497 IRNGTYDHDVYRDEA 511

HA2

3.4 Structural location of the positive peptides
To demonstrate the structural location of the epitopes recognized by SAB-100, we
mapped the identified epitopes on the HA structure (Figure 1). Peptides 72 and 73 (residues
285-303) from H1 are in the HA1 domain, while other positive peptides are in the HA2
subunit. All the peptides are in the ectodomain of HA except the epitopes represented by
the overlapping peptides (136/137/138). As can be seen from Figure 1, the peptides 72 and
73 containing both loop and β-sheet are located on the HA surface. Peptides (92/93/94)
consisting of α-helix and β-sheet are also presented on the HA surface. The epitope on the
HA surface are exposed to the humoral immune responses and prone to be targeted by both
polyclonal antibodies and monoclonal antibodies. Notably, the conserved region
recognized by SAB-100 in both H1 and H3 are shown in red in Figure 3.1. Some peptides
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recognized by SAB-100 are not shown in the structural model owing to the unavailable
structural information.

Figure 3.1 The 3D structural of these identified epitopes on the HA. HA1 was shown
in light blue, while HA2 was in wheat. Conserved regions, such as CD-helix, A-helix and
B-loop, were pointed by arrows. Residues 289-303 and 365-387 were shown in cyan and
pink, respectively. Note that the H1N1and H3N2 shared residues (peptide 93) were colored
in red.
3.5 Conservative analysis of the positive peptides

Figure 3.2 Conservative analysis of one highly conserved epitope recognized by SAB100. In our peptide ELISA, residues 370 –386 located in HA2 were reactive with SAB-
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100. In the logo, the height of each amino acid symbol indicates the relative frequency of
the amino acid at that position.
We assessed whether these amino acid residues constituting the epitopes were
conserved

among

all

subtypes

of

(http://weblogo.threeplusone.com/create.cgi
generated

from

35,505

HA

sequences

HA

by

[6,7]).
in

the

generating
623

the

web

representative

influenza

research

logo

sequences
database

(https://www.fludb.org) were analyzed. Our initial alignment (data not shown) indicated
that the peptides 72/73, 136/137/138 were variable in different HA subtypes, while
peptides 93 was highly conserved. Here we showed the conservation of the peptide 93 in
all the HA subtypes. The result indicated that the H370, N372, G375, G377, A379, A380,
D381, S384, T385, and Q386 were highly conserved in all the HA subtypes. Q371, Q374,
S376, Y378, and K383 were moderately conserved (>50%) in the strains analyzed. The
analysis of the amino acid residues conservation may provide novel insights into design of
a new avenue for inducing broad binding antibodies.

3.6 Discussion
Characterization of polyclonal antibodies is crucial for a better understanding of
humoral immunity against the antigens. However, epitope mapping can be a challenge
considering the complexity of polyclonal antibody binding. Multiple epitopes including
both continuous epitopes and discontinuous epitopes can mediate antibody binding.
Peptide ELISA assay used in this assay may give incomplete epitope mapping results as it
cannot detect the discontinuous epitopes [5]. The uncovered epitopes by peptide ELISA
are confined to the designed peptides. Recently, new methods are employed to map the
epitopes bound by polyclonal antibodies. For example, electron-microscopy-based method
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was developed to map novel epitopes [8]. These methods may provide a comprehensive
understanding of humoral responses and assist in the design and development of vaccines
and therapeutic agents.
One interesting observation of this study is that SAB-100 recognized a highly
conserved epitope in HA2 domain. Our conservative analysis showed that most residues in
this epitope are conserved in all the subtypes of HAs. It would be interesting to investigate
how substitutions in the epitope affect antibody binding. Given SAB-100 is a polyclonal
antibody with potent anti-influenza activity, multiple epitopes may be involved in antibody
recognition and antiviral activity. And therefore, investigations into how SAB-100’s
comprehensive epitope landscape can be a daunting task. Nevertheless, the high
conservation rates of the amino acid residues present in the identified epitopes for SAB100 reported in this study indicate that this polyclonal antibody may possess a broadspectrum activity against multiple influenza virus strains. Therefore, this polyclonal
antibody can be used for therapeutic purpose to combat influenza.
Future investigation of SAB-100 may focus on protective mechanisms. Our epitope
mapping indicated that the antibody could recognize epitopes in HA2. It may inhibit the
pH-triggered conformational change for membrane fusion, which needs to be confirmed
experimentally. Other protective mechanisms may be also employed by SAB-100 to limit
influenza virus infection, such as Fc-effector functions and viral entry inhibition, which
need further exploration.
Altogether, our peptide ELISA results showed that three epitopes in both H1 HA and
H3 HA were identified, with one epitope conserved in both H1 and H3 HAs. The highly
conserved amino acid residues (369-387) suggest this polyclonal antibody may have a
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broad binding ability with diverse strains of influenza A virus, which emphasize its
potential role as a therapeutic agent.
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Chapter 4:
Human Monoclonal Antibody Derived from Transchromosomic (Tc) Cattle
Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel
Conformational Epitope in the HA Head Domain
Abstract
Influenza remains a global health risk and challenge. Currently, NA inhibitors are
extensively used to treat influenza, but their efficacy is compromised by the emergence of
drug resistant variants. Neutralizing antibodies targeting influenza A virus surface
glycoproteins are critical components of influenza therapeutic agents and may provide
alternative strategies to the existing countermeasures. However, the major hurdle for the
extensive application of antibody therapies lies in the difficulty of generating nonimmunogenic antibodies in large quantities rapidly. Here, we report one human
monoclonal antibody, 53C10, isolated from transchromosomic (Tc) cattle which exhibits
potent neutralization and hemagglutination inhibition titers against different clades of H1
subtype influenza A viruses. In vitro selection of antibody escape mutants reveals that
53C10 recognizes a novel non-continuous epitope involving three amino acid residues,
glycine (G) at position 172, Serine (S) at position 207 and glutamic acid (E) at position
212.

Results from flow cytometry, neutralization assay, and HI assay consistently

supported a critical role for substitution of arginine at position 207 (S207R), which
mediated resistance to 53C10, while substitutions at either G172E or E212A did not alter
antibody recognition and neutralization. In fact, mutation of E212A may provide structural
stability for the epitope, while the substitution G172E probably compensates for loss of
fitness introduced by S207R. Our results offer novel insights into the mechanism of action
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of 53C10 and indicate the potential role of 53C10 in therapeutic treatment of H1 influenza
virus infection in humans.
4.1 Introduction
Influenza remains both a health risk and a global challenge for infectious disease.
Considerable morbidity and mortality are caused by influenza virus; it is estimated that
290,000-650,000 respiratory deaths are associated with influenza every year worldwide
[1]. Vaccines against influenza viruses are available and have been in use since the 1940’s
[2]. However, these vaccines vary in their effectiveness often due to differences between
the circulating virus and the isolate chosen for inclusion in the vaccine [3].
Influenza viruses, belonging to the Orthomyxoviridae family, are divided into four
genera: A, B, C, and D viruses [4,5]. Influenza A viruses are further divided into distinct
subtypes based on the antigenic variation of the two surface glycoproteins on the viral
membrane: hemagglutinin (HA) and neuraminidase (NA). 18 HA and 11 NA subtypes have
been detected in nature [6] and H1N1 influenza A viruses are the most prevalent strains
circulating in humans in the US during the 2019-2020 influenza season [7]. The H1 viruses
circulating in US swine population are classified into several distinct clades according to
antigenic differences in HA, including alpha, beta, gamma, delta1, delta2 and new
pandemic (npdm) clades [8]. This virus diversity may compromise vaccine efficacy,
underscoring the critical role of neutralizing antibodies with broad neutralizing spectrum
in combating influenza infections of humans.
Monoclonal antibody (mAb) therapy is a novel and promising technique against
multiple pathogens including, influenza viruses [9-11], Ebola virus [12,13], respiratory
syncytial virus [14] and human immunodeficiency virus [15,16]. The major hurdle for
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extensive application of mAb therapies lies in the difficulty of generating nonimmunogenic antibodies in large quantities rapidly. mAbs are usually generated from
animals or prepared from the plasma of human donors. However, mAb from a human
source is hampered by supply shortages and animal-derived mAbs suffer from severe side
effects since they are often immunogenic in humans [17]. Up to now, multiple strategies
have been employed to humanize animal-derived mAbs aiming to minimize foreign
immunogenicity, such as complementary determining regions (CDR) grafting and antibody
resurfacing [18]. It has been demonstrated that the CDR grafting can lead to a substantial
decrease in antibody affinity in many cases, whereas the comprehensive evaluation of
resurfaced antibody immunogenicity is not available now [19,20].
To overcome these obstacles, a transchromosomic (Tc) cattle platform capable of
expressing fully human, antigen-specific mAbs was developed [21]. In these genetically
engineered cattle, their immunoglobulin genes were knocked out and replaced by the entire
germline loci of human immunoglobulin heavy chain, lambda chain, and kappa chain [21].
Not only can this procedure produce human polyclonal antibodies in large quantities in a
time-efficient manner, these Tc cattle can also be used to produce mAbs that recognize
specific antigens of interest from a variety of viruses. This expands the potential application
in passive immune therapies, allowing for both broad, polyclonal approaches as well as
specific, monoclonal approaches to therapeutic treatment. Until now, Tc cattle have been
employed to generate antibodies with high in vivo therapeutic efficacy against diverse
viruses, such as middle east respiratory syndrome coronavirus (MERS-CoV) [22], Ebola
virus [23], hantavirus [24], Venezuelan equine encephalitis virus [25], and Zika virus [26].
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Therefore, the Tc cattle platform provides a feasible way to produce large amounts of fully
human antibodies rapidly and a valuable tool to combat emerging virus outbreaks.
Here we report a novel fully human monoclonal antibody (53C10) generated from Tc
cattle that is capable of neutralizing different clades of H1N1 influenza A viruses in vitro.
The results of our study collectively show that 53C10 binds with high affinity to a
conformational epitope in the HA globular head domain that blocks virus entry. The
characterization of this novel antibody presented in this study further suggests its role as a
potential therapeutic agent to treat H1 influenza infections in humans.
4.2 Materials and methods
4.2.1 Cells and viruses
Madin-Darby canine kidney (MDCK) cells and human embryonic kidney cells (293T)
were ordered from ATCC. These cells were passaged and grown in Dulbecco’s modified
Eagle’s medium (DMEM, HyClone) with the addition of 100 U/ml penicillin-streptomycin
(Gibco) and 10% fetal bovine serum (FBS, HyClone) at 37℃ with 5% CO2.
A/California/04/2009 (CA/04) was acquired from BEI Resources. The following swine
influenza A viruses: A/swine/Nebraska/A01399492/2013 (NE9492, GenBank accession
number: KF712462), A/swine/Oklahoma/A01134903/2011(OK4903, GenBank accession
number: CY114784), A/swine/Minnesota/A01349281/2013(MN9281, GenBank accession
number: KC844197), and A/swine/Illinois/A01047079/2010(IL7079, GenBank accession
number: CY114631), were ordered from the United States Department of Agriculture
(USDA). A/Swine/Minnesota/02053/2008 (MN02053, GenBank accession number:
CY082650) was isolated by Dr. Ben Hause. Viruses were grown in virus growth medium
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(VGM) containing1 µg/ml of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)trypsin (Thermo Fisher Scientific) and 0.3% bovine serum albumin (BSA, Sigma-Aldrich).
4.2.2 Recombinant H1 proteins
The baculovirus expressed recombinant H1 proteins of A/California/04/2009 (NR15749), A/swine/Iowa/15/1930 (FR-699), and B/Florida/4/2006 (NR-15748) were
obtained from BEI Resources.
4.2.3 Selection of in vitro escape mutants against monoclonal antibody 53C10
53C10-resistant mutant was selected by propagating CA/04 virus in presence of increasing
concentration of 53C10 antibody. In brief, MDCK cells were infected with CA/04 virus
and incubated for 1 hour at 37°C with 5% CO2. Then the medium was replaced by the
virus growth medium (VGM) with 53C10 and plates were incubated at 37°C until the time
when apparent cytopathic effect (CPE) was observed. The virus cultural supernatants were
then collected for next passage. The concentration of 53C10 was doubled after each
passage, and the selection process ended after 10 passages. Virus was propagated in the
absence of 53C10 antibody in parallel to detect any passage-related mutations. All viruses
from passage ten were sequenced to identify the amino acid mutations in all segments.
4.2.4 Viruses genes sequencing
The whole genomes of passage ten viruses were sequenced by the Illumina MiSeq
instrument as reported previously [5]. Briefly, viral RNA was extracted using TRAZOL
and then amplified by a universal inﬂuenza A ampliﬁcation kit (Life Technologies).
Nextera XT DNA library preparation kit and MiSeq reagent nano kit v2 (Illumina) was
used for library preparation. DNA libraries were loaded into a Miseq reagent cartridge for
sequencing.
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4.2.5 ELISA
ELISA was performed as previously described [36]. Briefly, high binding and flat
bottom ninety-six well plates (Thermo Fisher Scientific) were coated with recombinant HA
protein for 18 hours at 4°C. After washing plates with PBST (phosphate-buffered saline,
PBS with 0.05% Tween-20, Sigma-Aldrich) six times, the plates were blocked with 300 µl
/well blocking buffer (PBST with 0.2% bovine skin gelatin, Sigma-Aldrich) for 2 hours at
37°C. After six washes, the plates were incubated with the antibody 53C10 (two-fold
serially diluted in PBST with 0.01% gelatin) for 1 hour followed by an additional six
washes. 100 µl horseradish peroxidase (HRP)-conjugated goat anti-human IgG (BETHYL)
at 1:100,000 dilution was added to the plates and incubated for 30 min at 37°C. 100 µl
tetramethylbenzidine (TMB, SeraCare) was added as substrate and incubated in the dark
followed by the addition of 4M sulfuric acid to stop the reaction. The signal was detected
using an ELISA microplate reader (BioTek) at 450nm.
4.2.6 Reverse genetic system (RGS)
Eight bidirectional RGS plasmids of A/New York/1682/2009 were used to rescue the
virus as described previously [37]. The HA segment of CA/04 virus was amplified by RTPCR and then cloned into the pHW2000 vector to generate HA plasmid for “7+1” virus
rescue. A single point mutation or double mutations in the HA gene were introduced using
specific primers. The mutated plasmids were sequenced before virus rescue.
4.2.7 Indirect immunofluorescence assay (IFA)
MDCK cells cultured in chamber slides (LAB-TEK) were infected with the virus. 24
hours post-infection (h.p.i), cells were fixed with 80% acetone for 20 min at room
temperature and blocked with blocking buffer (PBST with 1% BSA) for an additional 1
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hour at 37°C. The first antibody, 53C10, was added at a 1:400 dilution to each of the wells,
and then the slides were incubated at 37°C for 1 hour. Following three washes with PBS,
goat anti-human fluorescein-conjugated secondary antibody (BETHYL) was added at a
1:1,000 dilution, followed by incubation at 37°C for 45 min. After washing the chamber
three times, 4’, 6-diamidino-2-phenylindole (DAPI, Invitrogen) was added and incubated
for 20 min at room temperature before data collection and analysis.
4.2.8 Fluorescence-activated cell sorting (FACS)
MDCK cells were infected with the virus. 24 h.p.i, the supernatant was discarded and
MDCK cells were collected followed by washing with PBS. Permeable buffer (BD
biosciences) was added to the cells and incubated for 1 hour at 4°C. Cells were collected
by centrifugation at 2,000 rpm for 5 min and evenly split into two tubes before
immunostaining. The anti-NP antibody (FR-667, international reagent resource) generated
from mouse was diluted at 1:250 and added to one tube to detect the percentage of virusinfected cells, while 53C10 antibody was diluted at 1:500 and added to the other tube. After
1-hour incubation at room temperature, the first antibody was removed and followed by
three washes with PBS. Bound antibodies were detected with goat anti-mouse FITC
(Thermo Fisher Scientific) and goat anti-human FITC (BETHYL) at 37°C for 45 min,
respectively. Following washes with PBS, the cells were suspended and fixed in 1%
paraformaldehyde (PFA, Polysciences). Flow cytometry was carried out on a FACS
Calibur (BD biosciences) and analyzed by cell quest software (BD biosciences). 20,000
events were analyzed in each sample.
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4.2.9 Western blotting
Recombinant HA proteins expressed from baculovirus were heated at 95°C for 10
minutes and then subjected to 12% SDS-PAGE. The gel was transferred to a nitrocellulose
membrane (Thermo Fisher Scientific) at 100V followed by 2 hours of blocking with 5%
nonfat milk at room temperature. The membrane was incubated with primary antibody
overnight at 4°C followed by incubation with goat anti-human secondary antibody (LICOR) for 1 hour at room temperature. The membrane was washed three times with PBST
(PBS and 0.1% Tween-20) after each incubation. Following the final washes with PBST,
antibody binding was detected using the Odyssey Infrared Gel Imaging System (LI-COR).
4.2.10 Virus neutralization assay
Virus neutralization assays were performed as previously described [36,38,39], with
slight modifications. In brief, the 50% tissue culture infectious dose (TCID50) of viruses
used in this assay was determined using MDCK cells followed by the dilution of viruses to
100 TCID50/100 µl with VGM. Antibody 53C10 was treated in Receptor-Destroying
Enzyme (RDE, Denka Seiken) for 18 hours, heat-inactivated, and two-fold serial-diluted
in PBS in a U-bottom 96 well plate (Thermo Fisher Scientific). Then 60 µl of 100
TCID50/100µl virus was added to each 53C10 dilution (60 µl) followed by 1-hour
incubation at 37°C in 5% CO2. After the incubation, 100 µl virus-53C10 mixture was
transferred to PBS-washed MDCK cells followed by additional incubation for 4 days. Viral
neutralization was evaluated with HA assay involving 1% turkey erythrocytes. Back
titrations, cell only control and negative antibody control were performed to confirm assay
reliability.
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4.2.11 Hemagglutination inhibition (HI) assay
HI assay was carried out in V-bottom 96-well plates as previously described [40].
Briefly, RDE-treated 53C10 was two-fold serial-diluted and incubated with an equal
volume of 4 HA units of H1 virus for 30 min at room temperature, then 1 % turkey
erythrocytes were added. The HI titer was determined as the highest antibody dilution that
exhibits complete inhibition of hemagglutination.
4.2.12 Virus replication assay
Monolayer MDCK cells were infected with influenza virus at a MOI of 0.01. At 1hour post-infection (h.p.i), cells were washed three times with PBS to remove unbound
virus before the addition of VGM. At the time points of 6, 12, 18 and 24 h.p.i, 100 µl of
supernatant were collected and kept in -80°C before titration.
4.2.13 Structural locations of the identified mutations in CA/04 HA
The 3D location of three mutant residues was generated by PyMOL software in the
context of the crystal structure of CA/04 hemagglutinin (PDB accession number: 3LZG).
4.2.14 Statistics analysis
In this study, the data were shown as means +/- standard errors. Statistical significance
evaluation was assessed by Student’s t test. *, p<0.05; **, p<0.01; ***, p<0.001.
4.3 Results
4.3.1 Generation of fully human monoclonal antibodies from the Tc cattle
A Tc bovine was immunized with A/California/7/2009 (H1N1), A/Victoria/361/2011
(H3N2), and B/Wiscosin/1/2010. Then, B cells were isolated from lymph tissue of the Tc
bovine and plated in 96 well plates followed by screening with the recombinant H1 protein
of A/California/04/2009 (H1N1) in ELISA. The influenza virus H1-reactive B cells were

66
cultured in vitro followed by the collection of the supernatants towards the production of
monoclonal antibodies that was used in this work. Purification and quantification of the
antibodies were conducted according to previous studies [24]. Briefly, the Tc bovine
plasma was thawed, pooled, and fractionated in an acidic environment and then filtered to
remove any non-IgG proteins. Next, the human IgG specific affinity chromatography was
employed for further purification at the pH of 7.5.
4.3.2 53C10 binds to the recombinant HA protein from different clades of H1
viruses in ELISA
To determine whether 53C10 antibody interacted with the HA protein from different
clades of H1, ELISA was performed using different clades of HA proteins produced by the
baculovirus expression system. In ELISA, the antibody was diluted using two-fold serial
dilutions and the recombinant HA protein from influenza B virus (B/Florida/4/2006Yamagata lineage) was used as a negative control. As shown in Fig. 1A, 53C10 antibody
was able to recognize the representative HA proteins from alpha and npdm clades with
high affinity. Remarkably, antibody binding still can be detected when the antibody was
diluted at 1: 105. We were unable to test reactivity against HAs from other H1 clades as
representative recombinant proteins were unavailable.
4.3.3 53C10 neutralizes different clades of H1 viruses in vitro
To assess whether 53C10 can neutralize various clades of H1 viruses, including alpha,
beta, gamma, delta1, delta2 and new pandemic (npdm), a set of in vitro virus-neutralizing
and hemagglutination inhibition (HI) assays was performed. The online swine H1 clade
classification tool (https://www.fludb.org) was used to classify the virus strains [27]. As
summarized in Fig. 1B, the results indicated that 53C10 exhibited potent neutralizing
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capability against the representative strains from npdm, alpha, beta and gamma clades with
neutralizing titer up to 1:1067, 1:533, 1:853 and 1:67 (average titer of three repeats),
respectively. In contrast, 53C10 failed to neutralize the representative viruses from delta1
and delta2 clades. This may be due to the fact that the cluster involving delta1 and delta2
clades is well separated and more divergent from the clusters involving alpha, beta, gamma
and npdm clades (Fig. 1C).
Next, the HI assay using different clades of H1 virus was performed to characterize
the spectrum of 53C10 reactivity. The HI assay showed consistent results with those
demonstrated in the virus neutralization assay. As shown in Fig. 1B, 53C10 displayed HI
titers against representative viruses from npdm, alpha, beta, and gamma clades, with the
HI titer of 1:640, 1:160, 1:320, and 1:20, respectively. Consistent with the neutralization
assay result, 53C10 showed no detectable HI titer against delta1 and delta2 clades.
Together, our results suggest that the antibody 53C10 may bind to HA protein and as a
result interfere with receptor binding and neutralize multiple clades of H1 subtype.
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Figure 4.1 53C10 neutralizes multiple H1 clades of influenza A virus. (A) Monoclonal
antibody 53C10 recognizes HAs from alpha clade and npdm clade. The baculovirus
expressed HAs of A/California/04/2009 and A/Iowa/15/1930 were subjected to ELISA
with monoclonal antibody 53C10. 53C10 was two-fold serial diluted. The baculovirus
expressed HA of strain B/Florida/4/2006 was used as negative control. (B) Neutralization
activity of 53C10 against representative strains from different clades of H1 viruses. The
online swine H1 clade classification tool (https://www.fludb.org) was employed to classify
the virus strains. (C) Phylogenetic analysis of the H1 representative stains by maximum
likelihood method in MEGA X. The phylogenetic tree with the highest log likelihood (-

69
9917.90) was generated in the Jones-Taylor-Thornton (JTT) model with a bootstrapping of
1000 replicates using the global swine H1 clade classification reference sequences [27]. In
the phylogenetic tree, strain name, isolated species and country, subtype and H1 clade were
shown. The H1 clades were labeled as alpha, beta, delta1, delta2, delta like, gamma,
gamma2, alpha beta gamma2 like, gamma2 beta like, other, npdm (new pandemic), NA
(not applicable) and ND (not determined) (www.fludb.org).

4.3.4 Monoclonal antibody 53C10 recognizes a conformational epitope on the HA
molecule
The neutralization and HI assays suggest the epitope of 53C10 antibody may overlap
with the receptor-binding site. To further investigate whether the epitope is comprised of
continuous or non-continuous amino acid residues, Western-blotting assay with 53C10 was
performed using the baculovirus-expressed HA protein. Prior to Western-blotting,
recombinant HA (rHA) of A/California/04/2009 (CA/04, H1N1) was denatured at 95°C
for 10 minutes. As shown in Fig. 2A, 53C10 antibody failed to react with CA/04 rHA at a
concentration of 1, 4, 16, 64, 256, 1024 ng, respectively, whereas a linear epitope-targeted
antibody, 63C7, was found to bind to the HA at a concentrations of 64, 256, and 1024 ng
(Fig. 2B), indicating that 53C10 likely recognizes a conformational epitope on the HA
protein. It is worth noting that when using a flow cytometry assay, we found that both
antibodies 53C10 and 63C7 bound to HA protein expressed in MDCK cells that were
infected with CA/04 with a similar affinity (Fig. 2C). This finding further supports our
position that 53C10 interacts with a non-linear epitope.
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Figure 4.2 Monoclonal antibody 53C10 recognize a conformational epitope on the HA
molecule. The recognition of baculovirus-expressed CA/04 HA by antibody 53C10 (Fig.
2A) and antibody 63C7 (Fig. 2B) were evaluated by Western blotting (WB) as described
in Materials and Methods. Below each lane is the amount of HA loaded. Molecular sizes
(Kd) were labeled to the left of the figure. Prior to WB, HA was denatured at 95°C for 10
minutes. (C) The binding of HA to 53C10 and 63C7 was determined in flow cytometry.
MDCK cells were infected by CA/04. 24 hours post infection, MDCK cells were evenly
split into four tubes which were stained individually using either no antibody control, the
antibody targeting NP protein (NP-Ab FR-667), 53C10 antibody, or 63C7 antibody. The
percentage of cells bound by each antibody was shown.
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4.3.5 In vitro selection and characterization of antibody escape mutants
To further map 53C10 epitope and elucidate the critical amino acid residues mediating
53C10’s recognition, we selected the antibody escape mutants using CA/04 in the presence
of increased concentrations of 53C10 antibody during the serial passage of the virus in
MDCK cells. Specifically, CA/04 wild type (WT) was propagated in the presence of 53C10
antibody. Antibody concentration was increased 2-fold in the subsequent propagations and
the virus sent for Miseq to determine full-genome sequence after 10 passages for the
identification of potential resistance-conferring mutations in all eight virus gene segments.
Sequence analysis revealed that the escape mutant possessed three mutations in the HA
segment after passage in the presence of the 53C10 antibody. Alternatively, there were no
mutations detected in other segments when compared to control cultures involving passage
of the virus in the absence of 53C10 antibody. The three HA segment mutations observed
in the escape mutant derived from passage 10 were G172E, S207R, and E212A (Fig. 3A),
which were located in the antigenic site Sa, receptor-binding site (RBS) and antigenic site
Sb, respectively (Fig. 3B) [28-31]. The H1 residue numbering was initiated from the first
methionine, as described previously [32,33]. To generate a pure population of the mutant
harboring these three mutations, we introduced these three mutations into our reverse
genetic system (RGS)-HA plasmid for virus rescue. The mutant, designated Escape, was
successfully rescued and used for further characterization.
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Figure 4.3 Escape mutant harboring three substitutions completely escape from
53C10 recognition. (A). Alignment of the HA sequences of CA/04 and the survived
antibody escape mutant. Three substitutions (G172E, S207R and E212A) identified from
the in vitro antibody selection assay were highlighted using boxes. (B). The structural
location of these three substitutions in the context of CA/04 HA (PDB accession number:
3LZG) is shown. Position G172E, S207R, and E212A were in the antigenic site Sa,
receptor-binding site (RBS) and antigenic site Sb, respectively. The influenza virus HA
binding sialic acid is shown as sticks. This figure was generated using PyMOL.

We performed immunofluorescence assay (IFA), flow cytometry, and virus
neutralization assay to confirm antibody evasion using the RGS-rescued Escape mutant. In
IFA, Escape mutant HA completely lost its binding to 53C10 as no immunofluorescent
signals were detected (Fig. 4A). Notably, similar levels of MDCK cells were infected with
CA/04 WT and Escape mutant as determined using anti-NP antibody (Fig. 4B).
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Figure 4.4 Binding comparison of the antibody 53C10 to CA/04 HA and escape
mutant HA in IFA. The chamber slide-cultured MDCK cells were infected by CA/04 WT
and Escape mutant. At 24h post infection, the cells were fixed with 80% acetone followed
by staining with the primary antibody: 53C10 (upper panels) and the antibody targeting NP
protein, (FR-667, lower panels). Virus-infected cells were detected by staining with NPspecific monoclonal antibody. DAPI was used to stain the nucleus blue. Scale bar: 20µm.
The remarkable reduction of 53C10’s recognition and neutralization for the mutant was
also observed using flow cytometry, neutralization assay and HI assay. As shown in Fig.
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5A-C, the escape mutant showed a complete loss of reactivity with 53C10 antibody when
compared to CA/04 WT in flow cytometry (Fig. 5A and 5B). Since no mutations in NP
segment were observed in the escape mutant virus, the percentage of virus-infected MDCK
cells could still be determined using anti-NP Ab (Fig. 5A and 5C). The percentage of
CA/04 WT- and Escape mutant-infected MDCK cells detected by NP-specific Ab are
82.89% and 94.22%, respectively, whereas the percentages of MDCK cells recognized by
53C10 were 91% and 1.1% (background level), respectively, suggesting that Escape
mutant bearing these three mutations can completely escape 53C10 recognition. In
addition, 53C10 exhibited no detectable neutralization and HI titers against Escape mutant
(Fig. 5D). Together, these results show that these three substitutions in CA/04 HA
abrogated the ability of 53C10 antibody to recognize and neutralize CA/04 WT virus.
To determine the impact of these three mutations on virus replication fitness, MDCK
cells were inoculated with Escape mutant and CA/04 WT viruses at a multiplicity of
infection (MOI) of 0.01. Supernatants (100 µl) were collected at 12, 24, 36, 48 and 60
hours post infection (h.p.i) to determine viral infectivity. The replication kinetics show that
the RGS-derived Escape mutant replicated more efficiently than the CA/04 WT virus in
MDCK cells (Fig. 5E).
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Figure 4.5 Characterization of RGS rescued Escape mutant. Quantitative comparison
of the binding of antibody 53C10 to CA/04 HA and Escape mutant HA using flow
cytometry. (A) Representative data of three independent experiments are presented.
MDCK cells were infected by CA/04 WT and Escape mutant and then stained by 53C10
to determine antibody binding (B). Virus infected cells were detected by staining with NPspecific monoclonal antibody (FR-667, C). Neutralization activity of 53C10 against Escape
mutant and CA/04 WT. HI titer against Escape mutant was undetectable in the
neutralization assay (D). Replication comparison of Escape mutant and CA/04 WT in
MDCK cells. MDCK cells were inoculated virus at an MOI of 0.01 and maintained for 60
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hours. Supernatant samples were collected at 12, 24, 36, 48 and 60 hours post infection and
evaluated in MDCK cells by TCID50 assay.

4.3.6 Role of individual substitutions in 53C10 neutralization and virus fitness
To assess the contribution of individual amino acid substitutions to 53C10 antibody
evasion, we attempted to rescue viruses bearing each individual amino acid substitution
and double amino acid substitutions in the context of the CA/04 HA backbone (Fig. 6A).
We were unable to rescue mutants containing the S207R mutations after 6 independent
attempts (Table 1). However, we successfully rescued three mutants that did not express
the S207R substitution. Thus, it appears that position 207 plays a critical role in mediating
receptor binding steps that initiate the infection cycle. Some substitutions as this position
may disrupt receptor binding and as a result significantly impair virus replication fitness.
Table 4.1 Mutants rescue frequency from reverse genetic system (RGS).
Mutants

Rescue frequency*

G172E

5/6

S207R

0/6

E212A

3/6

G172E S207R

0/6

G172E E212A

3/6

S207R E212A

0/6

*Rescue frequency was shown in numbers of successful mutant rescue/total attempts.
To further analyze the interaction of 53C10 Ab with the three rescued mutants, we
performed flow cytometry, neutralization, and HI assays. The mutant viruses expressing
G172E, E212A, and G172E/E212A reacted with 53C10 at a similar level as CA/04 WT
virus, suggesting that residues 172G and 212E have no impact on 53C10 antibody
recognition (Fig. 6B-C). Similarly, a neutralization assay showed that these mutants were
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neutralized by 53C10 similarly to CA/04 WT, indicating that substitutions at position 172
and 212 had no effect on 53C10 antibody recognition and neutralization. Besides, mutants
G172E, E212A and G172E/E212A showed same HI titer as WT (Fig. 6D). Collectively,
substitutions at position 172 and 212 are not critical for antibody binding affinity and
neutralization, underscoring the crucial role of position 207 in mediating 53C10 antibody
recognition and neutralization of influenza A virus.
We next determined the replication fitness of these rescued mutants in MDCK cells.
As shown in Fig. 6E, two mutants (G172E, G172E/E212A) displayed significant, 10-fold
higher titers than CA/04 WT and mutant E212A (p=0.029 at 36 hours post infection),
suggesting that substitutions at position 172 improve virus growth rate and, as a result, may
compensate for the loss of fitness introduced by S207R. In contrast, substitution of E212A
did not affect viral growth rate since mutant E212A displayed similar growth kinetics as
CA/04 WT virus in MDCK cells.
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Figure 4.6 Characterization of mutants with individual antibody-resistant mutations.
(A) To study the contribution of individual mutations to 53C10 evasion, six mutants were
designed. Single mutation and double mutations highlighted were designed to introduce
into the CA/04 WT virus. Dots indicate the identical residues observed when comparing
mutant sequences with the CA/04 WT virus. (B and C) Quantitative comparison of the
binding of antibody 53C10 to CA/04 HA and mutant HAs using flow cytometry. MDCK
cells were infected virus and then stained by 53C10 to determine antibody binding and NPspecific FR-667 antibody to quantify virus infected cells. (D) Neutralization and HI titers
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against CA/04 WT and the RGS-rescued mutants with individual antibody-resistant
mutations. (E) Replication comparison of CA/04 WT and the RGS-rescued mutants in
MDCK cells. MDCK cells were inoculated with virus at an MOI of 0.01 and supernatant
samples were collected at 12, 24, 36, 48 and 60 hours post infection followed by titration
in MDCK cells by TCID50 assay.

4.3.7 Sequence conservation of 53C10 antibody recognition residues
We analyzed sequence variations by retrieving the sequences from the influenza
research

database

(IRD,

https://www.fludb.org).

Sequence

logos

(https://weblogo.berkeley.edu/, [34,35]) were generated to visualize the conservation of
53C10 antibody recognition residues in each H1N1 clade (Fig. 7). In sequence logos, the
proportion of each residue was indicated by the height of amino acid symbol. The antibodybinding residues are highly conserved in all H1 clades except for delta1 and delta2 clades,
which show a good correlation with our neutralization data. 53C10-resistant delta1 and
delta2 strains differ significantly in these three residues from other 53C10-sensitive H1
clades which may explain why delta1 and delta2 clades cannot be recognized and
neutralized by 53C10. For position 207, delta2 strains have an alanine (A) while other
clades have a serine (S) or threonine (T) at this position. Based on our observations, it
seems that the substitution T207 has no substantial effects on the recognition of HA by
monoclonal antibody 53C10, which can be expected considering the similarity in side
chains in the structures of serine and threonine amino acid residues. Interestingly, the HA
from some delta1 strains harboring T207 cannot be recognized by 53C10 in this study,
which indicate a context-dependent recognition mechanism by the 53C10 antibody that is
primarily driven by the three critical amino acid residues identified here. For position 172,
glutamic acid (E) rather than glycine (G) was found in alpha, beta, and gamma clades that
are sensitive to 53C10 antibody-mediated neutralization. As stated above, this substitution
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has no obvious impact on the 53C10 activity. Conservation analysis also revealed that
strains from delta1 and delta2 contain E, while the remaining clades maintain an alanine
(A) at position 212. Since A was observed in the escape mutant at position 212, and alpha,
beta, gamma, and npdm clades harboring alanine were all recognized by 53C10, this
confirms that position 212 was not critical for 53C10 binding.

Figure 4.7 Conservative analysis of identified three antibody resistant-related
residues among different clades of H1 viruses. Sequence logos were employed to
demonstrate the conservation of three antibody resistant-related residues (highlighted by
arrows) in influenza strains from H1 clades. The proportion of individual residues in each
clade was indicated by the height of the amino acid symbol. For conservative analysis, HA
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sequences from each clade were retrieved from Influenza Research Database (IRD) and
aligned for generating sequence logos (www.fludb.org).

4.4 Discussion
Influenza remains an international health concern and economic threat, and
vaccination is the most effective way to combat influenza virus infection. Due to a concern
that efforts in influenza vaccination are often challenged by new antigenic variants,
developing effective antibody-based countermeasures has gradually emerged as an
attractive direction that can be complementary to the current treatment of influenza
patients. In this study, we demonstrated that fully-human monoclonal antibody 53C10
generated from Tc cattle recognizes a novel conformational epitope in the HA head and
exhibits an impressive cross-clade (H1) neutralizing activity. Our results also revealed that
a mutant carrying three amino acid substitutions in the HA head domain was capable of
mediating total escape from 53C10 antibody recognition. Furthermore, results from our
experiments indicated that only residue S207 is critical for 53C10 binding and
neutralization activity whereas residue G172 seems to compensate for the fitness costs
introduced by the S207R mutation, while E212A may provide structural stability to the
epitope. To our knowledge, the combination of these three mutations has not been
previously documented for their contribution to antibody evasion.
The discontinuous epitope we identified here overlaps with one known epitope
reported previously [41]. In that study, the epitope-targeting antibodies could neutralize
A/WSN RG/33 (H1), A/Aichi/2/68(H3), and A/gull/Maryland/704/77 (H13), which are not
neutralized by 53C10 antibody. The functional discrepancy supports our position that while
these epitopes overlap, the epitope of 53C10 identified in our study is different from the
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one defined previously. We further demonstrate that G172E, S207R, and E212A
substitutions are capable of mediating total 53C10 antibody evasion. It was reported that
residue 207 (also described as position 193, using numbering without inclusion of the
signal peptide) is located in the 190-helix, which is one conserved region that mediates
receptor-binding [30,31,42]. Antibody binding to this region inhibits viral replication by
interfering with receptor binding and ultimately blocks virus entry. Therefore, S207 plays
a critical role in virus replication and direct binding to this residue can significantly block
receptor-binding. Substitutions in HA 207 position may reduce receptor-binding avidity to
escape from antibody recognition at the significant cost of viral fitness [43]. The fact that
we failed to rescue some viruses containing the S207R mutation highlights a critical role
for this residue in virus entry and replication.
We demonstrated that two substitutions, G172E and E212A, had no substantial impact
on 53C10 antibody recognition and neutralization, but may compensate for the fitness costs
of the S207R substitution. Mutant virus rescued from RGS harboring these two
substitutions showed a more rapid growth rate when compared to the wild type virus in our
replication kinetics experiment. Notably, the mutant only carrying mutation E212A
showed similar replication kinetics as the CA/04 WT virus in MDCK cells. We speculate
this mutation may provide structural stability to the epitope recognized by 53C10. In sharp
contrast to the E212A substitution, mutants carrying the G172E substitution alone display
10-fold increased titers, suggesting that residue 172 is critical to compensate for the
reduced fitness of the S207R substitution. Consistent with previous reports, the
introduction of G172E substitution (G155E in their study) can lead to high growth rate of
A/New Jersey/76 in eggs [33]. Similarly, the virus isolate A/California/07/2009, which
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contains G172E, can grow much better in eggs [44]. Here we demonstrated that the
introduction of G172E substitution can increase CA/04 growth rate by 10-fold in MDCK
cells based on viral replication kinetics, and this 10-fold increase may restore the virus
fitness that was reduced by the S207R mutation. Taken together, results of our experiments
pinpoint a critical role for HA position 172 in virus replication.
Selection of antibody escape mutants in vitro is commonly employed to identify
conformational epitopes recognized by neutralizing antibody, and the amino acid
mutations identified in escape mutants are considered to be residues constituting
conformational epitopes. However, our findings suggest that some mutations may not
engage directly in antibody binding, and may rather be related to viral fitness or required
to maintain the structural integrity critical for display of a functional epitope. Since HA
globular head-binding, neutralizing antibody inhibits viral entry by binding to the RBS,
substitutions in RBS may enable the virus to evade neutralizing antibody pressure while
also leading to reduced virus fitness or even a replication-incompetent nature. In this
regard, it can be envisioned that an antibody escape mutant can acquire compensatory
mutations to recover virus fitness at the cost of major resistance mutations [45-47]. Here
we confirmed that the compensatory mutations play no essential role in antibody
recognition and neutralization; hence they are more likely non-epitope mutations. Nonepitope mutations may emerge as these residues are able to tolerate mutations, and may
also have an impact on proper presentation of conformational epitope structures. Therefore,
future characterization of conformational epitopes by selection of escape mutants needs to
distinguish compensatory mutations from the residues constituting the conformational
epitope.
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It would be important and interesting to investigate the mechanisms by which these
compensatory mutations restore virus fitness. Kosik et al. demonstrated that glycosylation
might play a critical role in compensating for fitness loss of major antibody resistance
mutations [43]. Glycosylation may be responsible for the viral growth rate increase in this
study, and residue 170 was reported to contact with glycans [48]. Negatively charged
glutamate at residue 170,171 and 172 may present a better way to communicate with
glycans, which as a result facilitates viral growth in MDCK cells [44].
Neutralizing antibody may facilitate the emergence of antibody-resistant mutants, as
has been observed for multiple pathogens, such as influenza virus, ZIKA virus [49], HIV
[50,51], respiratory syncytial virus [52], hepatitis C viruses [53,54], and porcine
reproductive and respiratory syndrome virus [55]. Influenza virus HAs have high plasticity
and undergo frequent antigenic drifts to evade humoral immunity [56]. The high antigenic
drift rate in influenza viruses may be due to the selective pressure exerted by neutralizing
antibodies. In fact, selection by neutralizing antibodies is proposed as one primary force
that drives the evolution of human influenza HA [57]. Most influenza virus-specific
neutralization antibodies target the HA globular head and block viral entry. Influenza virus
can evade antibody pressure by acquiring one or several mutations that can either eliminate
or significantly reduce antibody binding affinity [58]. The accumulation of these mutations
leads to antigenic drift, or antigenic variation, which may substantially reduce a vaccine’s
effectiveness [59,60]. The antigenic drift/variation poses a major health concern and makes
influenza prevention and control more challenging. It is worth noting that the combination
of multiple antibodies or the mixture of antibody and influenza drugs may serve as an
effective way to prevent the emergence of escape mutants. Prabakaran et al. reported that
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the combination of two antibodies recognizing different epitopes can prevent the formation
of escape mutants in mice and enhance therapeutic efficacy against H5N1 infection [61].
Shen et al. also demonstrated that the combination of antibody C7G6-IgM and oseltamivir
could confer increased protective efficacy that is better than either agent administered alone
[62]. Although no evidence shows that oseltamivir can inhibit the replication of antibodyresistant mutants, it is tempting to speculate that variants resistant to one treatment may
still be inhibited by the other treatment since these treatments inhibit viral replication
through distinct mechanisms.
There are several limitations in our study. First, characterization of 53C10 antibody’s
protective efficacy in vivo is necessary in future studies. Second, it is worthwhile to select
for and characterize antibody-resistant mutants in an animal model as use of an animal
model or cell lines may result in distinct mutation profiles. Third, the conformational
epitope recognized by 53C10 still needs to be mapped precisely. Selection of antibody
escape mutants only shows one critical residue mediating 53C10 binding; the molecular
nature and composition of this novel conformational epitope remains unclear. Further
characterization of the conformational epitope may assist with the rational design of
effective antibodies to combat influenza epidemics.
In summary, we report here that a human monoclonal antibody (53C10) generated
from Tc cattle is broadly active against several clades of viruses within the H1 subtype. By
in vitro selection of antibody escape mutants, we identified a novel discontinuous epitope
that overlaps with the RBS of HA protein. Further characterization demonstrated that two
escape substitutions do not affect antibody binding, rather they compensate for the loss of
fitness introduced by the escape mutation that is critical for antibody evasion. In this regard,
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our observations broaden our understanding of antibody escape mechanisms in their
description that some mutations are critical for disruption of antibody binding sites, while
other mutations are essential for either compensating the loss of fitness or for maintaining
structural integrity of an epitope. Further characterization of 53C10 antibody’s mechanism
of action and its antiviral activity in animal models may offer useful information for the
development of future antibody-based therapeutic agents against influenza A virus
infections in humans.
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Chapter 5:
Trimer Interface Binding Human Monoclonal Antibody Recognize Diverse H1
Hemagglutinins (HAs) of Influenza Viruses
Abstract
Influenza virus poses a serious concern for global health considering its exceptional
ability in evading pre-existing immunity. Formulation of effective influenza vaccines can
be complicated by both antigenic shift to a different subtype of hemagglutinins (HAs) and
antigenic drift within a particular HA subtype. Therefore, there is an urgent need for broadspectrum antibody based therapeutic agent to cure influenza infections. Here, we describe
the properties of a human monoclonal antibody (mAb), 38C2, generated from
transchromosomic (Tc) cattle that recognizes diverse influenza A HAs from subtype H1.
Based on the enzyme-linked immunosorbent assay (ELISA) using HA peptide array and
3-D structural modeling, we demonstrated that 38C2 targeted a novel epitope located on
the trimer interface of influenza virus HA protein. This broad HA-binding property was
also confirmed by flow cytometry assay coupled with infected MDCK cells with diverse
influenza A viruses. Despite the broad recognition of HA subtypes, 38C2 monoclonal
antibody demonstrated no detectable neutralizing activity against H1N1 virus in both
hemagglutination inhibition (HI) and virus neutralization assays. Further investigation of
38C2’s mechanism of action showed that this monoclonal antibody induced appreciable
antibody-dependent cellular cytotoxicity (ADCC) in vitro. The broad-spectrum binding
property and the in vitro ADCC activity shall pave the way for further exploring 38C2 as
a potential therapeutic agent to treat influenza infection of humans.
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5.1 Introduction

Influenza viruses create a serious challenge for global health, and it is estimated that
influenza viruses cause 290,000 to 650,000 fatalities yearly worldwide [1]. The high
mortality is exemplified by the 1918 Spanish influenza outbreak which killed millions of
lives and the 2009 influenza pandemic with an estimated 284,000 deaths in the first year
[2-4]. Influenza may trigger severe pneumonia and other respiratory illnesses to the
patients [5].

Influenza viruses can infect pigs and cause swine influenza. Currently, H1N1, H1N2,
and H3N2 are the most prevalent subtypes of swine influenza virus (SIV) circulating and
causing respiratory disease in the United States [6,7]. SIV belongs to the
Orthomyxoviridae family which comprises of influenza A, B, C and D viruses [8,9]. SIV
infected pigs may show symptoms like high fever, runny nose, impaired appetite and
persistent coughing [10]. Notably, more severe symptoms can be observed if coinfections
with bacteria or other viruses occur [11]. Mortality rate associated with SIV infection in
pigs is generally low, but morbidity rate can be as high as 100% and infected pigs can be
recovered within one to two weeks [12]. Swine can transmit the influenza virus to human,
fatal pneumonia have been observed in several human patients infected with SIV in the
past [11]. Hence, SIV poses a potential zoonotic threat to human health.
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Small inhibitors targeting M2 and NA have been developed to treat influenza. The
usage of M2 inhibitors is suspended due to the rapid emergence of resistant mutants.
Currently, NA inhibitors, such as oseltamivir, zanamivir, peramivir, and laninamivir, are
used for influenza treatment. However, their efficacy can completely lose if administrated
after 2 days of symptom onset [13]. Their extensive usage may also be hindered by drug
resistance mutations and adverse drug reactions. Thus, alternative countermeasures to
treat influenza is urgently needed.

The influenza surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA),
are the major antigenic determinants. The HA glycoprotein plays an essential role in
receptor binding, membrane fusion and progeny virus assembly, and it is also the
principal target of antibodies. HA is a highly plastic glycoprotein and undergoes
antigenic drift in a high frequency, which leads to the reduced or limited protection of
strain-specific vaccines [14,15]. Furthermore, the annual influenza vaccine may not be
effective against antigenic drifted variants [16,17]. Therefore, broadly cross-reactive
antibody-based therapeutics may provide a plausible option to treat influenza infections.

In this study, the Tc cattle platform was utilized for human antibodies generation.
Our observations indicated that one mAb, 38C2, recognized diverse influenza A
hemagglutinin proteins of H1 subtype, which was confirmed by flow cytometry and
recombinant HA protein-based Enzyme-linked immunosorbent assay (ELISA). Further
investigation revealed that the minimal epitope comprised of amino acid residues 214–
226 that is located in the HA trimer interface. Although mAb 38C2 demonstrated no
detectable neutralizing activities against H1N1 and H3N2 viruses, it induced appreciable
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ADCC activity in vitro. The characterization of this novel epitope, broad-spectrum
binding activities, and the ADCC activity of 38C2 support its role as a promising
therapeutic agent for the treatment of human influenza virus infections.

5.2 MATERIALS AND METHODS
5.2.1 Cells and viruses.
293T cells and Madin-Darby canine kidney (MDCK) cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, HyClone) supplemented with 10% fetal
bovine serum (FBS, Gibco) and penicillin-streptomycin (Gibco). The
A/California/04/2009, A/WSN/1933, A/swine/North Carolina/3793/08 and
B/Florida/4/2006 were propagated in MDCK cells.
5.2.2 Generation of mAb 38C2
The mAb used in this study was kindly provided by SAB biotherapeutics company
(Sioux falls, SD). A Tc bovine was immunized with A/California/7/2009 (H1N1),
A/Victoria/361/2011 (H3N2), and B/Wiscosin/1/2010. Then, B cells were isolated from
lymph tissue of the Tc bovine and cultured in vitro followed by the collection of the
supernatants towards the production of monoclonal antibodies.
5.2.3 Peptide array
The peptide array was kindly provided by BEI Resources, NIAID, NIH (Cat#NR15433). The peptide array consisted of 80 overlapping peptides covering the entire
sequence of influenza A virus H1N1 A/California/04/2009 HA1 protein. Each synthetic
peptide contained 15 amino acids residues and overlapped with the adjacent peptides by
11 amino acids residues. Dimethyl sulfoxide (DMSO) (Fisher Scientific) was added to
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each peptide to get 1 mg/ml solution. Additional peptides used in this study were
synthesized by GenScript (https://www.genscript.com/).
5.2.4 Recombinant HA proteins
The recombinant HA(rHA) protein of H1N1 A/swine/Iowa/15/1930 (Cat#FR-699),
expressed from baculovirus expression system, was provided by International Reagent
Resources (IRR, https://www.internationalreagentresource.org). A/California/04/2009
rH1 (Cat#NR-15749), A/New York/18/2009 rH1 (Cat#NR-19441), A/Czech
Republic/32/2011 rH1 (Cat#NR-42486), A/Toulon/1173/2011 rH1 (Cat#NR-34587), and
B/Florida/4/2006 rHA (Cat#NR-15748) were obtained from BEI resources
(https://www.beiresources.org).
5.2.5 Enzyme-linked immunosorbent assay (ELISA)
The ELISA was performed as described previously[7]. Each dissolved HA peptide
(0.5 μg) from the peptide array was diluted in coating buffer (NaHCO 3/Na2CO3 buffer,
pH=9.6) and then transferred to 96-well enzyme immunoassay high-binding plates
(Thermo) for overnight coating at 4℃. Plates were washed with PBST (PBS with 0.1%
Tween-20) six times and then blocked with 300 μl blocking buffer (PBST with 0.2%
gelatin (SIGMA)) for 2h at 37℃. After the incubation, plates were washed with PBST
six times, and then incubated with the antibody, 38C2 (1:300 dilution in PBST containing
0.01% gelatin) for 1h at 37℃ followed by further washing with PBST. 100 μl of 1:10,000
diluted goat anti-human IgG specific antibody conjugated to HRP (BETHYL) were
added to the plates and incubated at 37℃ for 30 min. Plates were then washed again and
antibody binding was detected by addition of 100 μl of tetramethylbenzidine (TMB,
KPL) for 15min in the dark and stopped by adding 50 μl 4M sulfuric acid. The optical
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density (OD) was read by an ELISA microplate reader (BioTek) at an absorbance of 450
nm.
5.2.6 Flow cytometry analysis
MDCK cells grown on six T-25 cm2 flasks were infected with influenza A virus. At
24 h post infection, cell monolayers were collected followed by blocking in FACS buffer
(containing PBS with 0.5% bovine serum albumin (BSA, Sigma-Aldrich)) for 2 hours. A
250 μl volume of human monoclonal antibody, 38C2, was added at a 1:300 dilution to
the infected cells and incubated at room temperature for 1 hour. Following three washes
with FACS buffer, 250 μl fluorescein labeled goat anti-human IgG secondary antibody
(BETHYL) was added at a 1:1,000 dilution. After 1 hour incubation at room temperature,
the secondary antibody was removed and washed three times with FACS buffer. The
cells were kept in 4°C with 1% paraformaldehyde (PFA, Polysciences). Cells were
analyzed by a FACS Calibur (BD biosciences) and 20,000 events were measured from
each sample. To test the binding between intracellular HA and 38C2, FACS buffer was
replaced by permeable buffer (BD biosciences).
5.2.7 Structural location of novel epitope identified from ELISA
To locate the novel epitope in the 3- dimensional (3-D) structure of the CA/04 HA
protein, the HA crystal structure [PDB: 3LZG] was downloaded from the Protein Data
Bank ( https://www.rcsb.org/ ), and the epitope was shown on the structure using
PyMOL.
5.2.8 ADCC reporter bioassay
The ADCC activity was evaluated in vitro using the commercial ADCC reporter
bioassay kit from Promega as described previously [18-20]. Experimentally, MDCK cells
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were seeded onto white flat-bottom 96-well assay plate (Corning) and then infected with
influenza virus. 24 hours post infection, the VGM was aspirated, and twenty-five
microliters of antibody dilutions were added to each well. The antibody was serially
diluted three-fold in ADCC assay buffer containing RPMI 1604 and 4% low IgG serum.
Subsequently, the MDCK cells were incubated with the antibody at 37°C for 30 min.
Then, 75,000 specialized Jurkat cells were added to each well and the plate was incubated
at 37°C for 6 hours. Seventy-five microliters of Bio-Glo luciferase substrate were added
to each well and incubated at room temperature for 5 min in dark. Then, the
luminescence was read by GloMax multi-detection system (Promega). Fold of luciferase
induction was calculated under the guidance of kit protocol.

5.3 Results
5.3.1 mAb 38C2 binds broadly to diverse recombinant HA proteins of H1 subtype.
To investigate the binding spectrum of 38C2, baculovirus expressed HAs from
diverse influenza A viruses were tested in ELISA. 38C2 bound to H1 HAs with high
binding affinity (Fig. 1A). Also, 38C2 recognized representative HAs from diverse clades
of influenza A virus, such as the alpha and npdm clades . The B/Florida/4/2006
recombinant HA was used as the negative control in ELISA, showing no binding activity.
The broad binding was further confirmed by the Western blot analysis using the
baculovirus expressed HAs. The results revealed that 38C2 recognize diverse H1, which
is consistent with our ELISA results (Fig. 1B).
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Figure 5.1A. Monoclonal antibody 38C2 recognizes diverse H1 HAs in ELISA. In the
peptide ELISA, the recombinant HA proteins expressed from baculovirus were used to
coat the ELISA plates. The antibody, 38C2 was two-fold serial diluted. The
B/Florida/4/2006 recombinant HA was used as the negative control.
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Figure 5.1B. 38C2 recognized a linear epitope on the H1 HA. Below each figure is the
amount of HA subjected to the Western blotting (WB). The recombinant HAs were
denatured at 95℃ for 10 min. The dilution of 38C2 was labeled.

5.3.2 mAb 38C2 recognized diverse HAs in both surface and intracellular forms

Figure 5.2. The recognition of intracellular and surface HA expressed in virusinfected MDCK cells by 38C2 antibody. The level of 38C2 antibody-binding by CA/04
virus was set at 1. 0 (i.e., 100%). Antibody-binding acitivty for each of indicated viruses
was normalized by comparison with CA/04 virus. Permeable bufffer was used for
evaluation the binding between intracellular HA and 38C2, while non-permeable buffer
was used to determine the binding between surface HA and 38C2.

To confirm the binding between 38C2 and H1, MDCK cells were infected by
influenza A virus and followed by the antibody binding evaluation in flow cytometry.
The result showed that 38C2 reacted with diverse H1s of influenza A viruses. Among
these tested H1s, CA/04 HA has higher binding affinities to 38C2, followed by the
A/WSN/1933 HA, and A/swine/North Carolina/3793/08 HA. 38C2 binding to surface
expressed H1s was demonstrated in a similar pattern as the intracellular H1s.
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5.3.3 mAb 38C2 induces a potent ADCC activity in vitro
Fc-effector functions, especially ADCC, serve as a critical protective mechanism
agaisnt influenza infection [21-23]. Antibodies against HA stalk region can confer
protection via inducing ADCC activity by Fc domain [21]. Recent studies have shown that
antibodies targeting HA head can also elicit strong ADCC activity [24,25]. Given that no
neutralization activity was shown by 38C2 (data not shown), we hypothesized that this
broad-spectrum high-affinity binding may enable 38C2 develop appreciable ADCC
activities. We assessed the ADCC activity of 38C2 against CA/04, A/WSN/1933, and
A/swine/North Carolina/3793/08 (SIV) and B/Florida/4/2006 infected MDCK cells using
a commercial ADCC bioassay kit (Promega), in which ADCC activity was indirectly
measured by the fold of induced luciferase expression. 38C2 exhibited a substantial
ADCC activity against CA/04, moderate ADCC activity against A/WSN/1933, relatively
weaker ADCC activity aginst SIV, and no ADCC activity against B/Florida/4/2006, the
negative control strain.
We envisioned that the potency of ADCC activity induced by 38C2 may relate to the
binding affinity between 38C2 and the HA. 38C2 exhibited relative higher ADCC
activity to CA/04, moderate ADCC activity to A/WSN/1933 and weak ADCC activity to
SIV. Similarly in flow cytometry, 38C2 recognized CA/04 HA at the highest binding
affinity, followed by A/WSN/1933, and SIV. Therefore, the potency of ADCC activities
revealed a similar trend to that of 38C2 binding affinity to HAs, indicating that the
potency of ADCC activity may be largely determined by the binding affinity between
38C2 antibody and HA.
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Figure 5.3 38C2 induces detectable ADCC activities against diverse H1 viruses. The
potency of ADCC activities were determined by a commercial kit which measured the
luciferase induction in the effector cells. B/Florida/4/2006 served as a negative control.
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5.3.4 Identification of the epitope recognized by 38C2 in peptide ELISA

Figure 5.4 Identification of an epitope in the HA protein of A/California/04/2009 by
peptide ELISA. A. The HA comprised of the signal peptide, HA1 and HA2. B. A set of
80 peptides derived from A/California/04/2009 strain was grouped to 16 peptides pools
(PPPs). These pools were coated to the 96-well ELISA plate. 38C2 and the negative
antibody were then added at 1:300 dilution. Reactivity of peptides to 38C2 as determined
by the different OD value (P-N) between 38C2 (P) and its negative control (N). C. Each
individual peptides from the postive peptide pool were analyzed for 38C2 binding.
The peptide ELISA involving overlapping peptides provides an efficient way to
identify epitopes recognized by antibodies. Here, peptide ELISAs were performed to map
the epitope recognized by 38C2 using A/California/04/2009 (CA/04) HA peptide array. A
set of synthetic peptides with 11 residues overlapping with the adjacent peptides covering

104
the HA1 was tested for its reactivity against 38C2 (Fig. 4A). Firstly, peptide pools were
screened for 38C2 binding and each peptide pool comprised of five adjacent peptides
(Fig. 4B). One peptide pool 51-55 (PPP51-55) containing peptide 51-55 was recognized
by 38C2 in the peptide ELISA. Binding of 38C2 to individual peptides in this peptide
pool were further assessed in the ELISA and the result revealed that only peptide 54 can
be recognized by 38C2 (Fig. 4C).
To identify the minimal epitope recognized by 38C2, a new set of ELISAs were
performed (Fig. 4D). A subset of truncated peptides with amino acid(s) deleted from both
N-terminal and C-terminal was subsequently manufactured and examined. The result
showed that mAb 38C2 bound to peptide214-226 but failed to react with peptide215-225,
peptide216-224 and peptide217-223, suggesting that peptide214-226 consisted of 13 amino acids,
spanning HA214-226, may be the minimal epitope required to react with 38C2 (Fig.4E).
To confirm whether peptide214-226 is the minimal epitope, we synthesized another two
truncated peptides, peptide214-225 and peptide215-226, to examine their binding to 38C2
(Fig.4F). The result demonstrated that these two truncated peptides cannot be recognized
by 38C2, indicating that peptide214-226 spanning HA214-226 is the minimal epitope
recognized by 38C2 (Fig. 4G). Clearly, only peptide 54 containing the entire minimal
epitope was reactive to 38C2 whereas peptide 53 and peptide 55 were not, thereby
indicating that peptide 54 was the only peptide reactive to 38C2. The novel epitope
identified here may assist with the future design of broad-spectrum ADCC-based
antibodies.
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Figure 5.4 Identification of an epitope in the HA protein of A/California/04/2009 by
the peptide ELISA. D and F. Sequences of these truncated peptides with amino acid
deleted from both N-terminal and C-terminal. E and G. The reactivities of truncated
peptides with 38C2.
5.3.5 Conservation of the epitope in H1 influenza viruses

Figure 5.5 Amino acid sequence alignment of the epitope 214TYVFVGSSRYSKK226.
253 representative sequences of 14,786 H1 sequences were analyzed. The comparative
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analysis results were shown in sequence logo
(http://weblogo.threeplusone.com/create.cgi, [26,27]). In the logo, the height of each oneletter abbreviation of amino acid indicates the relative frequence of the amino acid at that
position.
To determine the conservation of this novel epitope identified in this study, we
aligned the amino acid sequences from H1 viruses (Fig. 6). 253 sequences were selected
as representative sequences of 14,786 H1 sequences downloaded from Influenza
Research Database (https://www.fludb.org). The comparative analysis indicated that the
novel epitope spanning HA214 - 226 is highly conserved in H1 viruses. The amino acid
residues at positition 215,216,218, 221 and 223 are conserved in more than 98% of the
analyzed H1 sequences, which suggest that these residues may play an important role in
maintaining HA function or structural configuration. More than 94% of the analyzed H1
sequences contained either an Ala or a Thr at position 214, a Ser or a Phe at position 217,
a Ser or a Thr at position 220 and a Arg or a Lys at position 226, which seem not
significantly to alter antibody 38C2 binding gaven that the strong binding between 38C2
and the HA of WSN33 occurred.
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5.3.6 Structural location of the epitope on the HA protein

Figure 5.6 The identified epitope is displayed in Ribbons representation of
A/California/04/2009 HA (PDB: 3LZG). One monomer was colored to illustrate the
identified epitope (blue, residues 214- 226) and the conserved regions (A-helix in
darkcyan, CD-helix in goldrod, fusion peptide in cyan). The other two monomers were
shown in gray. The receptor, sialic acid, was shown in the figure.
The ribbon representation of CA/04 HA was used to locate the minimal epitopes
recognized by 38C2 (Fig. 6). The different colors in Fig. 6 indicated the conserved
regions of the HA protein. The identified epitope containing loop and beta-sheet was
located on the interface of the HA trimer. This epitope does not overlap with receptorbinding site (RBS), which may explanin that 38C2 recognizing this epitope is ineffective
in neutralizing H1N1 viruses.

5.4 Discussion
Antibody is a valuable tool for HA antigenicity investigation, and more importantly,
antibody is a safe therapeutic candidate in the treatment of severe influenza infections.
Antibody therapy can be combined with anti-influenza drugs, which can induce a robust
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antiviral efficiency [28]. Numerous studies were conducted to benefit influenza virus
infected patients by developing antibodies that can be used as novel antiviral molecules.
A prerequisite for human therapeutic antibody is that the antibody must be a human
antibody or humanized to reduce its immunological risk. Here, the Tc cattle platform
developed by SAB Biotherapeutics company was employed to produce fully human
antibody, which shows substantial advantages over other humanized antibody production
strategies. First, this platform can produce large quantities of human monoclonal
antibody in a timely manner [29]. Second, this platform is capable of generating specific
mAbs targeting an interested protein from various viruses, including the emerging virus,
like the Middle East respiratory syndrome coronavirus (MERS-CoV) [30].
In this study, we report a human monoclonal antibody (38C2) generated from Tc
cattle shows broadly cross-reactive to diverse H1 proteins. 38C2 can recognize HA
proteins from multiple H1N1 viruses in both ELISA and flow cytometry. Subsequent in
vitro ADCC assay revealed that 38C2 can induce ADCC activities against diverse H1
viruses. A panel of synthetic peptides covering the HA1 of the H1N1 CA/04 virus was
utilized to localize the linear epitope recognized by 38C2. We identified the peptide
214

TYVFVGTSRYSKK226 of HA was the minimal epitope for 38C2 binding. Our study

may pave the way for using 38C2 as a potential therapeutic molecule for treatment of
influenza virus infections in humans.
Three-dimensional structural analysis show that the epitope is located on the trimer
interface. Since the epitope may be inaccessible to the antibody from HA trimer sides, we
propose that 38C2 may bind to the epitope from the top of a HA trimer. Most antibody
bind to the receptor binding site in the HA head domain or the stalk domain, antibodies
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binding to the trimer interface are much rare considering the limited accessibility of this
region by the humoral response. Nevertheless, Bangaru et al. recently showed that trimer
interface is at least partially accessible to the immune system [24]. Further
characterization of antibodies targeting the trimer interface may facilitates the
development of future vaccine and therapeutic agents.
Historically, it was commonly accepted that antibodies can only confer protection
against influenza virus infection by inhibiting virus attachment. Recent studies reveal that
antibody may provide protection via multiple mechanisms, such as viral and endosomal
membrane fusion inhibition, progeny virus budding inhibition, and Fc-effector function
[31-35]. Here, 38C2 mAb cannot induce neutralizing activities against H1N1 virus in vitro

(data not shown). The explanation is that the epitope recognized by 38C2 is not located in
the receptor binding site (RBS) but in the trimer interface, therefore, it cannot interfere
with receptor binding. Further characterization indicated that 38C2 possesses ADCC in
vitro. Until now, most ADCC-mediating antibodies target the HA stalk domain [21,36].
Here we show that one antibody, 38C2, binding to the trimer interface can also elicit
ADCC activity. Our study emphasizes the important role of HA head in inducing ADCCmediating antibodies.
In addition to ADCC, nonneutralizing antibodies may also can provide protection
through other Fc-effector functions, like antibody-dependent phagocytosis (ADP) [37].
Besides the mechanisms mentioned above, the complement system also play a significant
role in eliminating influenza virus infected cells. Some HA-specific human monoclonal
antibodies bind to infected cells and lyse these cells by activation of the complement
(complement-dependent lysis, CDL) [38-40]. Strikingly, small molecules, like tripartite
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motif-containing 21 (TRIM21), bind to antibodies with high affinity and cause
degradation of diverse pathogens including virus and bacteria [41-45]. Together, all these
mechanisms need to be well characterized and incorporated into existing anti-influenza
measures to limit or cure influenza virus-related infections.
We have not performed a in vivo experiment to measure the protective efficacy of
38C2 due to the unavailability of perfect animal models. As stated above, human mAb
38C2 demonstrated no detectable neutralizing activities but exhibited potent ADCC in
vitro, which is the only mechanism to confer protection. The commonly used animal
model to study ADCC in influenza research, mouse, may not work for this project.
Firstly, 38C2 is a human antibody, which may not be recognized by Fc-receptor bearing
cells in mouse as mouse express their Fc-receptors in a way that is considerably distinct
from their counterparts in humans [46]. Secondly, only mouse-adapted virus can be used
to infect mice since they are not the natural hosts. Therefore, it will be difficult to
evaluate human antibody therapeutic efficacy based on a mouse model.
In conclusion, we have identified one human mAb that reacted to diverse HAs of H1
subtype. Our data also revealed a novel epitope in HA1 located in the HA trimer
interface. Furthermore, this human mAb also induced a potent ADCC activity in vitro.
The broadly cross-reactive property of 38C2 suggest its potential utility in protection
against influenza virus infections of humans.
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Chapter 6. Conclusions
Influenza viruses present a major challenge to public health worldwide. The therapeutic
application of influenza virus inhibitors is often compromised by the emergence of drugresistant variants. Antibodies, especially humanized antibody or fully human antibody,
may serve as a potential therapeutic agent to limit influenza virus infection and spread in
humans. The Tc cattle platform used for human antibody generation in this study
demonstrated advantages over traditional antibody generation strategies, in terms of largescale production and less time consumption. By using this platform, numerous monoclonal
antibodies and polyclonal antibodies were generated against influenza viruses and
characterization of these antibodies revealed their crucial role as therapeutic agents to treat
human influenza. First, we mapped the epitopes bound by the polyclonal antibody SAB100 and our data proved that one epitope is highly conserved among different subtypes of
HAs, suggestive of its broad binding and therapeutic potential. Second, our
characterization of monoclonal antibody 53C10 showed its broad binding to diverse H1
subtypes and the results of our expeirments further demosntarted its high neutralization
titers against alpha, beta, gamma, and new pandemic clades. In additon, the in vitro
selection experiments for the identification of escape mutants using the 53C10 revealed
that three amino acid substitutions contributed to the antibody evasion. Further
characterization suggested that two amino acid substitutions may not directly mediate
antibody binding or escape but may serve as compensatory substitutions for virus
replication fitness. Third, we also found that some monoclonal antibodies were nonneutralizing as measured in hemagglutinin inhibition and neutralization assays. Our
characterization of monoclonal antibody 38C2 emphasized a crucial role of non-
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neutralizing antibody in influenza viral therapeutics and revealed that 38C2 may confer
protection via antibody-dependent cellular cytotoxicity. Further characterization suggested
that this antibody can bind to diverse H1 HAs in flow cytometry and enzyme-linked
immunosorbent assay by recognizing a novel epitope located in the HA trimer interface.
Further inveatigation of human antibodies derived from Tc cattle should result in
preclinical development of these novel antibodies towards treatment of human influenza.

